

NATIONAL QUALITY FORUM

Resource Use Measure Evaluation 1.0 January 2011

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the evaluation criteria are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

Resource Use Definition:

- Resource use measures are broadly applicable and comparable measures of input counts—(in terms of units or dollars)-- applied to a population or population sample
- Resource use measures count the frequency of specific resources; these resource units may be monetized, as appropriate.
- The approach to monetizing resource use varies and often depends on the perspective of the measurer and those being measured. Monetizing resource use allows for the aggregation across resources.

NQF Staff: NQF staff will complete a preliminary review of the measure to ensure conditions are met and the form has been completed according to the developer's intent. Staff comments have been **highlighted in green.**

TAP/Workgroup (if utilized): Complete all **yellow highlighted** areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: *If there is no TAP or workgroup, the SC also evaluates the subcriteria (yellow highlighted areas).*

Steering Committee: Complete all **pink** highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the subcriteria are met (TAP or Steering Committee)

High (H) - based on the information submitted, there is high confidence (or certainty) that the criterion is met

Moderate (M) - based on the information submitted, there is moderate confidence (or certainty) that the criterion is met

Low (L) - based on the information submitted, there is low confidence (or certainty) that the criterion is met

Insufficient (I) - there is insufficient information submitted to evaluate whether the criterion is met, e.g., blank, incomplete, or information is not relevant, responsive, or specific to the particular question (unacceptable)

Not Applicable (NA) - Not applicable (only an option for a few subcriteria as indicated)

Evaluation ratings of whether the measure met the overall criterion (Steering Committee)

Yes (Y)- The overall criteria has been met

No (N)-The overall criterion has NOT been met

High (H) - There is high confidence (or certainty) that the criterion is met

Moderate (M) - There is moderate confidence (or certainty) that the criterion is met

Low (L) - There is low confidence (or certainty) that the criterion is met

Recommendations for endorsement (Steering Committee)

Yes (Y) - The measure should be recommended for endorsement

No (N)-The measure should NOT be recommended for endorsement

Abstain (A)- Abstain from voting to recommend the measure

TAP/Workgroup Reviewer Name:
Steering Committee Reviewer Name:
Staff Reviewer Name(s):
NQF Review #: 1574 NQF Project: Endorsing Resource Use Standards- Phase II

BRIEF MEASURE INFORMATION
Measure Title: Episode of care for management of chronic congestive heart failure over a 12 month period
Measure Steward (IP Owner): American Board of Medical Specialties Research and Education Foundation, 222 N. LaSalle St., Suite 1500, Chicago, Illinois, 60601
Brief description of measure: Resource use and costs associated with management of congestive heart failure (CHF) care over a one-year period. Patients are identified in a management phase of CHF by including patients with CHF in the year prior to the measurement year and measuring CHF-related resource use and costs during the measurement year.
Resource use service categories: Inpatient services: Inpatient facility services Inpatient services: Evaluation and management Inpatient services: Procedures and surgeries Inpatient services: Imaging and diagnostic Inpatient services: Lab services Inpatient services: Admissions/discharges Ambulatory services: Outpatient facility services Ambulatory services: Emergency Department Ambulatory services: Pharmacy Ambulatory services: Evaluation and management Ambulatory services: Procedures and surgeries Ambulatory services: Imaging and diagnostic Ambulatory services: Lab services Durable Medical Equipment (DME)
Brief description of measure clinical logic: Resource use and costs associated with management of congestive heart failure (CHF) care over a one-year period. Patients are identified in a management phase of CHF by including patients with CHF in the year prior to the measurement year and measuring CHF-related resource use and costs during the measurement year.
<i>If included in a composite or paired with another measure, please identify composite or paired measure:</i>
Subject/ Topic Areas: Cardiovascular
Type of resource use measure: Per episode
Data Type: Administrative claims Other

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
A. Measure Steward Agreement. <i>The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</i>	A
A.1. Do you attest that the measure steward holds intellectual property rights to the measure? (If no, do not submit) Yes	
	Y <input type="checkbox"/> N <input type="checkbox"/>

<p>A.2. Please check if either of the following apply:</p> <p>A.3. Measure Steward Agreement.</p> <p>Agreement signed and submitted</p> <p>A.4. Measure Steward Agreement attached:</p>	
<p>B. Maintenance.</p> <p><i>The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. (If no, do not submit)</i></p> <p>Yes, information provided in contact section</p>	<p>B</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>C. Purpose/ Use (All the purposes and/or uses for which the measure is specified and tested:</p> <p>Quality Improvement (Internal to the specific organization)</p>	<p>C</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>D. Testing.</p> <p><i>The measure is fully specified and tested for reliability <u>and</u> validity (See guidance on measure testing).</i></p> <p>Yes, reliability and validity testing completed</p>	<p>D</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>E. Harmonization and Competing Measures.</p> <p><i>Have NQF-endorsed measures been reviewed to identify if there are related or competing measures? (List the NQF # and title in the section on related and competing measures)</i></p> <p>Yes</p> <p>E.1. Do you attest that measure harmonization issues with related measure (either the same measure focus or the same target population) have been considered and addresses as appropriate? (List the NQF # and title in the section on related and competing measures)</p> <p>No related measures</p> <p>E.2. Do you attest that competing measures (both the same measure focus and the same target population) have been considered and addressed where appropriate? No competing measures</p>	<p>E</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>F. Submission Complete.</p> <p><i>The requested measure submission information is complete and responsive to the questions so that all the information needed to evaluate all criteria is provided.</i></p>	<p>F</p> <p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>Have all conditions for consideration been met? Staff Notes to Steward (if submission returned):</p>	<p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>Staff Notes to Reviewers (issues or questions regarding any criteria):</p>	
<p>File Attachments Related to Measure/Criteria:</p> <p>Attachment: Attachment: S5_Data Dictionary-634343457134531287.pdf Attachment: Attachment:</p>	

Attachment:
 Attachment:
 Attachment:
 Attachment:
 Attachment: 10.1_Risk adjustment method-634339238228454379.pdf
 S12_sample score report.pdf
 Attachment: SA_Reliability_VValidity Testing CHF Chronic.pdf

IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in performance.

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All subcriteria must be met to pass this criterion.

Eval
 Rating

High Impact

IM1. Demonstrated high impact aspect of healthcare:

Affects large numbers
 A leading cause of morbidity/mortality

IM1.1. Summary of evidence of high impact:

Heart failure is a chronic progressive disease. It is a major growing public health problem in the United States. Approximately 5 million patients in this country have heart failure and over 550,000 patients are diagnosed with heart failure for the first time each year. According to the 2007 American Heart Association(1), there is an estimated 23 million people with heart failure worldwide.

The prevalence of heart failure has increased as population ages. Data from the Framingham Study(2) showed that the incidence appears to increase with age and higher in men than in women. Hypertension and coronary heart disease are the two most common conditions predisposing to heart failure.

Data from the Resource Utilization Among Congestive Heart Failure (REACH) study (3) showed an average increase in the prevalence of heart failure from 1989 to 1999 of 1/1000 for women and 0.9/1000 for men. Likewise, there has been a three to four-fold rise in the rate of hospitalization for heart failure from 1971 to 1999. African Americans have significantly higher rates of new onset HF and suffer poorer long-term survival compared to whites.

In the United States, \$2.9 billion annually is spent on drugs for the treatment of heart failure.

Assessing prognosis in HF is the subject of much research, and compared with other chronic states this has proven very difficult, particularly in patients with preserved left ventricular function. HF is a chronic progressive disease with less than 50% of patients living five years after their initial diagnosis and less than 25% are alive at 10 years.

The association of nonfatal hospitalization and subsequent mortality rates in chronic HF patients with reduced or preserved left ventricular ejection fraction (LVEF) was studied in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)(4) trials. Mortality rate was increased after HF hospitalizations, even after adjustment for baseline predictors of death. The increased risk of death was highest within one month of discharge and declined progressively over time.

Readmissions (5) are frequent for HF, and poor compliance (6) is an important contributing factor.

The Institute of Medicine and AQA have identified congestive heart failure (CHF) as one of 20 conditions that should be considered priority areas in need of quality improvement based on its relevance to a significant volume of patients, its impact on those patients, and the perception of opportunity to significantly improve the quality of related care. CHF had also been previously identified as a priority area in other national initiatives including the VA's Quality Enhancement Research Initiative, HRSA's Health Disparities Collaboratives, and the Quality Improvement Program at CMS (7). In addition, CHF episodes tend to be relatively high-resource episodes – the direct and indirect costs of CHF for the approximately 5 million Americans living with CHF are approximately \$33 billion annually, or \$6,600 per patient (8).

1a

H
 M
 L
 I

IM1.2. Citations for evidence of high impact cited in IM1.1.:

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009;119:e391-479.
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993;22:6A-13A.
3. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. *J Am Coll Cardiol* 2002;39:60-9.
4. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation* 2007;116:1482-7.
5. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. *Heart* 1998;80:437-41.
6. Opasich C, Rapezzi C, Lucci D, et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). *Am J Cardiol* 2001;88:382-7.
7. Priority Areas for National Action: Transforming Health Care Quality. Institute of Medicine. Karen Adams and Janet Corrigan Editors. March 10, 2003.
8. Patient Health Status and Costs in Heart Failure: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). *Circulation*, Jan 2009; 119: 398 - 407.

IM2. Opportunity for Improvement

IM2.1. Briefly explain the benefits envisioned by use of this measure:

To identify actionable information on the underlying causes of differences in patterns of care for CHF, it is useful to examine resource use and costs during an episode of care. If results from these analyses can provide clear and actionable information on which components of care can (or should) be reduced and which components of care can (or should) be increased, this information can help reduce spending while maintaining or even improving clinical quality and outcomes. This measure can be used to identify and, if necessary, address unwarranted variability in the resources used to treat CHF patients annually. In addition where gaps in utilization occur leading to suboptimal quality, education and care coordination can be implemented.

IM2.2. Summary of data demonstrating variation across providers or entities:

- Krumholz et al found readmission after a hospitalization for CHF is common among Medicare beneficiaries, with 44% readmitted within 6 months.(1)
- In a separate study, Krumholz and colleagues found that a formal education and support intervention substantially reduced adverse clinical outcomes and cost for patients with heart failure; the intervention was associated with a 39% decrease in hospital readmissions.(2)
- Reis and colleagues studied the pattern of care performed by generalists and cardiologists at a university teaching hospital. They found that generalists' patients had fewer in-hospital diagnostic tests and shorter lengths of stay, but had a 1.7-fold increase of readmission for CHF within a six month period. Cardiologist-provided care was associated with more diagnostic tests, longer hospital stays and improved clinical outcomes. (3).
- Shah and colleagues examined variation in utilization of implantable cardioverter-defibrillator (ICD) and biventricular pacemaker therapy within 134 U.S. hospitals participating in GWTG Heart Failure registry, an overall ICD use of 20% was found, with rates ranging from 1% to 35%. Hospital characteristics associated with ICD use were the availability of other advanced therapies such as percutaneous coronary intervention, CABG and heart transplant, larger bed sizes and academic affiliation.(4)
- Joynt, et al. conducted a retrospective study on Medicare fee for service patients with CHF and found that hospitals that treat a high volume of CHF patients produced higher quality of care and better outcomes, but at a higher cost. (5)
- A study by Simons et al showed a 4% of length of stay (LOS) variation due to the differing disease management practices across hospitals.(6)
- A study by Cook et al, found that patients at community health centers are less likely to receive cardiology consultations. Overtime, patients who receive cardiology consultation perform better than those patients who do not receive consultation.(7)

IM2.3. Citations for data on variation:

1b

H
M
L
I

1. Krumholz HM, Parent EM, Tu N et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. *Arch Intern Med* 1997;157:99-104.
2. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. *J Am Col Cardiology* 2002;39:83-89.
3. Reis, S. E., Holubkov, R., Edmundowicz, D., et al., (1997). Treatment of patients admitted to the hospital with congestive heart failure: Specialty-related disparities in practice patterns and outcomes. *Journal of the American College of Cardiology*, 30:733-8.
4. Shah, B., Hernandez, A.F., Liang, L., et al., (2009). Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure. *Journal of the American College of Cardiology*, 53:416-22.
5. Joynt, K.E., E.J. Orav, and A.K. Jha, The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. *Ann Intern Med*, 2011. 154(2): p. 94-102.
6. Simons, W.R., et al., Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. *Clin Ther*, 1996. 18(4): p. 726-46; discussion 702.
7. Cook, N.L., et al., Differences in specialist consultations for cardiovascular disease by race, ethnicity, gender, insurance status, and site of primary care. *Circulation*, 2009. 119(18): p. 2463-70.

IM2.4. Summary of data on disparities by population group:

There are noted disparities in CHF care among racial/ethnic minorities and women. Fewer women and African Americans are offered implantable defibrillators and coronary angiography than their white male counterparts (1-3). African Americans have higher rates of and mortality from CHF than whites. Mortality due to heart failure is about 2.5 times higher in African Americans than whites less than 65 years of age (4). Davis and colleagues found that for the period of 1991-1998, African Americans had preventable hospitalizations for angina at rates three times higher than other racial/ethnic groups, 7 times higher for hypertension, and 7-8 times higher for congestive heart failure.(5) Jolly, et al., studied prevalence and mortality rates of heart failure, AMI and stroke across the age spectrum among African Americans and whites. They found that in the 35-44 age group, African Americans had nearly double the prevalence of cardiovascular disease than whites, but the gap closed with older ages--socioeconomic and clinical factors mediated some, but not all, of the excess prevalence among young to middle aged African Americans (6). In a study assessing the influence of demographic variables on the utilization of LVAD, Joyce, et al., found that age, female gender, black race and admission to a non-academic center adversely affected access to this therapy(7). Results from a study by Daniels et al, found that Black patients are discharged from the ED with higher B-Type natriuretic peptide levels than Whites. Blacks are also more likely than Whites to be perceived as New York Heart Association class I or II. Even after controlling for clinical variables, the severity of heart failure in Black patients was underestimated. (8) Cook et al, studied differences in specialist consultations for cardiovascular disease and concluded that Women, Blacks, Hispanics, and Medicaid recipients receive poorer overall care than men, whites, and privately insured patients over time. In addition, Black patients had fewer follow-up consultations than Whites (9) Brown, et al noted that, compared with White Medicare enrollees in 2000, the likelihood of an inpatient admission for heart failure was 1.5 times greater among Black Medicare enrollees, 1.2 times greater among Hispanic Medicare enrollees, and 0.5 times less likely among Asian Medicare enrollees after controlling for age and sex. Compared with White patients hospitalized with heart failure, Black and Hispanic (but not Asian) patients were less likely than White patients to die in a hospital.(10)

IM2.5. Citations for data on disparities cited in IM2.4:

1. Curtis, L.H., Al-Khatib, S.M., Shea, A.M., et al., (2007). Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. *JAMA*, 298(13):1517-24.
2. Hernandez, A.F., Fonarow, G.C., Liang, L., et al., (2007). Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. *JAMA*, 298(13):1525-32.
3. Thomas, K.L., Al-Khatib, S.M., Kelsey, R.C., et al., (2007). Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of $\leq 35\%$. *American Journal of Cardiology*, 100(6); 924-9. Epub 2007 June 27.
4. Williams, R. A., (2009). Cardiovascular disease in African American women: A health disparity issue. *Journal of the National Medical Association*, 101(6), 536-540.
5. Davis, S.K., Liu, Y., & Gibbons, G.H. (2003). Disparities in trends in hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: Implications and benchmarks. *American Journal of Public Health*, 93:447-455.
6. Jolly, S., Vittinghoff, E., Chattopadhyay, A., et al., (2010). Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. *The American Journal of Medicine*, 123:811-818.

<p>7. Joyce, D.L., Conte, J.V., Russell, S.D., et al., (2009). Disparities in access to left ventricular assist device therapy. <i>Journal of Surgical Research</i>, 152:111-117.</p> <p>8. Daniels, L.B., et al., B-type natriuretic peptide (BNP) levels and ethnic disparities in perceived severity of heart failure: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study of BNP levels and emergency department decision making in patients presenting with shortness of breath. <i>J Card Fail</i>, 2006. 12(4): p. 281-5.</p> <p>9. Cook, N.L., et al., Differences in specialist consultations for cardiovascular disease by race, ethnicity, gender, insurance status, and site of primary care. <i>Circulation</i>, 2009. 119(18): p. 2463-70.</p> <p>10. Brown, D.W., et al., Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. <i>Am Heart J</i>, 2005. 150(3): p. 448-54.</p>	
<p>IM3. Measure Intent</p> <p>IM3.1. Describe intent of the measure and its components/ Rationale (including any citations) for analyzing variation in resource use in this way</p> <p>While documentation of regional variability in the overall costs of care reveals that inefficiencies exist in the healthcare system, it does not provide actionable information on the underlying causes of these differences or how they can be reduced. One potential solution is to focus on episode-based resource use and costs so that variations within a particular clinical area can be examined and areas of variability can be optimized. Moreover, episode-based resource measures can be combined with surrogate measures of quality care to identify highly efficient care where quality is high and costs are low. With this information, all parties involved (consumers, purchasers, and providers) can optimize treatment decisions that affect the balance of costs and quality of care.</p>	<p>1c</p> <p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p>
<p>IM4. Resource use service categories are consistent with measure construct</p> <p><i>Refer to IM3.1. & all S9 items to evaluate this criteria.</i></p>	<p>1d</p> <p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Importance to Measure and Report</i>?</p>	
<p>Steering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i>, met? Rationale:</p>	<p>Y <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>

<p align="center">SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES</p>	
<p>Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented.</p>	
<p align="center">MEASURE SPECIFICATIONS</p>	
<p>S1. Measure Web Page: <i>Do you have a web page where current detailed measure specifications can be obtained?</i></p> <p>Yes http://www.healthqualityalliance.org/hvhc-project/cost-care-measurement-development</p> <p>S2. General Approach <i>If applicable, summarize the general approach or methodology to the measure specification. This is most relevant to measures that are part of or rely on the execution of a measure system or applies to multiple measures.</i></p>	<p>Eval Rating 2a1/2b1</p>

The ABMS REF episode-based resource use measures were created in an open and transparent manner with input from a wide range of clinical experts, methodologists, health care economists and other stakeholders. The measure development process involved a series of deliberate steps where participating clinicians took into account the natural progression of a condition and existing best practices before carefully considering how to best use administrative claims data to construct the episode. They aimed to identify clinically homogenous populations so that the measures would be sensitive to provider decisions and existing practice protocols for like patients. Workgroup members were then asked to conceptualize the measure specifications based on their combined knowledge of guidelines, evidence, and clinical experience. The workgroups helped to define the denominator, duration, clinically relevant services and attribution of each episode as related to the clinical progression and treatment of the condition. Project staff then worked to translate the concepts into detailed written measure specifications and test the measures on a commercial database. The workgroups subsequently re-convened via a series of conference calls to review data analyses, share expert opinions, consider additional evidence-based literature, revise and finalize the measure specifications. Each measure was developed independently and, as such, they are not summative.

Attachment:

S3. Type of resource use measure:

Per episode

S4. Target Population:

S4.1. Subject/Topic Areas:

Cardiovascular

S4.2. Cross Cutting Areas (HHS or NPP National health goal/priority)

Care Coordination

S5. Data dictionary or code table

Please provide a web page URL or attachment if exceeds 2 pages. NQF strongly prefers URLs. Attach documents only if they are not available on a web page and keep attached file to 5MB or less.

Data Dictionary:

URL:

Please supply the username and password:

Attachment: S5_Data Dictionary-634343457134531287.pdf

Code Table:

URL:

Please supply the username and password:

Attachment:

S6. Data Protocol (Resource Use Measure Module 1)

The measure developer must determine which of the following data protocol steps: data preparation, data inclusion criteria, data exclusion criteria, and missing data, are submitted as measure specifications or as guidelines. Specifications limit user options and flexibility and must be strictly adhered to; whereas guidelines are well thought out guidance to users while allowing for user flexibility. If the measure developer determines that the requested specification approach is better suited as guidelines, please select and submit guidelines, otherwise specifications must be provided.

Data Protocol Supplemental Attachment or URL:

If needed, attach document that supplements information provided for data protocol for analysis, data inclusion criteria, data exclusion criteria, and missing data (Save file as: S6_Data Protocol).

All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.

URL: <http://www.healthqualityalliance.org/hvhc-project/cost-care-measurement-development>
Please supply the username and password:
Attachment:

S6.1. Data preparation for analysis

Detail (specify) the data preparation steps and provide rationale for this methodology.

Guidelines : Approach to Data Cleaning:

If a standardized cleaning methodology or logic for the claims data exists, users are encouraged to apply the existing methodology, or conversely, encouraged not to remove data cleaning steps already implemented. If however, organizations impute missing data, we recommend using only non-imputed data.

Rationale: Each organization will be more familiar with the nature of their data therefore any standard cleaning procedures are likely to be appropriate. Imputation can produce unpredictable biases in the results.

S6.2.Data inclusion criteria

Detail initial data inclusion criteria and rationale(related to claim-line or other data quality, data validation, e.g. truncation or removal of low or high dollar claim)

Guidelines : Paid claims with non-missing enrollee identification numbers, primary procedure and diagnosis codes should be included in the measure.

Note: The ABMS REF resource use measures are constructed based on date of service, not date of payment. Therefore, we recommend applying the measures to finalized or “closed” datasets so that complete claims histories during the measurement period are captured in the data.

Including enrollees with at least 24 months of continuous medical and pharmacy benefit enrollment during the identification year and the measurement year is recommended. However, the measure has been tested on enrollees with at least 320 total days of coverage during each year. If precise information regarding persons’ total days of coverage is not available, it is recommended that measure implementers estimate this information to the best of their ability using available data elements (e.g., monthly enrollment indicators). This approach is based on the similar eligibility requirements used by NCQA for HEDIS measure denominators.

S6.3. Data exclusion criteria

Detail initial data exclusion criteria and rationale (related to claim-line or other data quality, data validation, e.g. truncation or removal of low or high dollar claim)

Guidelines : Beyond the standard data cleaning steps, we recommend that claim lines with missing or zero quantity values be set to a quantity of one and claim lines missing enrollee identification variables, primary diagnosis and procedure codes, and service date be eliminated. We also recommend eliminating all rejected or unpaid claims. Because a single provider id could have multiple specialties, we also recommend generating a uniform specialty for all providers by assigning each provider the specialty which is most frequently observed from all their Evaluation and Management visits.

Rationale: Converting missing or zero quantities to a minimum value of 1 allows for the pricing of these services. Claim lines missing enrollee identifiers, or primary procedure and diagnosis codes cannot be attributed to an individual, and without procedure and diagnosis codes, services cannot be properly identified and categorized. The resource use measures are intended to track costs to the payer, not general or societal costs, so rejected or unpaid claims should be eliminated.

Standardizing the specialty of all providers eliminates the possibility that providers are classified as one specialty for one enrollee and another specialty for others.

S6.4. Missing Data

Detail steps associated with missing data and rationale(e.g., any statistical techniques used)

Guidelines : Users are encouraged to eliminate claim lines missing enrollee identification variables or primary procedure and diagnosis codes. We do not recommend using any imputation methods to replace missing data.

Rationale: Claim lines missing enrollee identifiers cannot be attributed to an individual, and without procedure and

diagnosis codes, services cannot be properly identified and categorized. Imputation of missing information could introduce bias into the measure, so we do not recommend the use of imputed data.

S7. Data Type: Administrative claims

Other

S7.1. Data Source or Collection Instrument

Identify the specific data source/data collection instrument (e.g. name of database, clinical registry, collection instrument, etc.)

Sources for administrative claims: commercial databases, CMS databases

Standardized price tables: Users can download tables from the NCQA website (see url below) or use the guidelines in the technical appendix of the written measure specifications to create their own standardized prices.

S7.2. Data Source or Collection Instrument Reference

(Please provide a web page URL or attachment). NQF strongly prefers URLs. Attach documents only if they are not available on a web page and keep attached file to 5MB or less)

URL: <http://www.ncqa.org/tabid/1092/Default.aspx>

Please supply the username and password:

Attachment:

S8. Measure Clinical Logic (Resource Use Measure Module 2)

The measure's clinical logic includes the steps that identify the condition or event of interest and any clustering of diagnoses or procedures. For example, the diagnoses and procedures that qualifies for a cardiac heart failure episode, including any disease interaction, comorbid conditions, or hierarchical structure to the clinical logic of the model. (Some of the steps listed separately below may be embedded in the risk adjustment description, if so, please indicate NA and in the rationale space list 'see risk adjustment details.')

Clinical Logic Supplemental Attachment or URL:

If needed, provide a URL or document that supplements information provided for the clinical framework, co-morbid interactions, clinical hierarchies, clinical severity levels, and concurrency of clinical events

URL: <http://www.healthqualityalliance.org/hvhc-project/cost-care-measurement-development>

Please supply the username and password:

Attachment:

S8.1. Brief Description of Clinical Framework

Briefly describe your clinical logic approach including clinical topic area, whether or not you account for comorbid and interactions, clinical hierarchies, clinical severity levels and concurrency of clinical events.

Resource use and costs associated with management of congestive heart failure (CHF) care over a one-year period. Patients are identified in a management phase of CHF by including patients with CHF in the year prior to the measurement year and measuring CHF-related resource use and costs during the measurement year.

S8.2. Clinical framework

Detail any clustering and the assignment of codes, including the grouping methodology, the assignment algorithm, and relevant codes and rationale for these methodologies.

The following steps were used to create the clinical framework for the measure.

Step 1: Identify patients that meet the following criteria during the identification period and measurement years: Two ambulatory visits for CHF-related care with at least one visit > 1 month prior to the measurement year. These ICD9 codes, present in a primary or secondary diagnosis field, will be used to identify CHF patients, regardless of

corresponding CPT codes (see also Table CHF-A in written measure specification): Rheumatic heart failure (congestive) ICD9: 398.91; Malignant Hypertensive Heart Disease with CHF: ICD0: 402.01; Benign Hypertensive Heart Disease with CHF; ICD9: 402.11; Hypertensive Heart Disease with CHF; ICD9: 402.91; Hypertensive Heart and Renal Disease, Malignant, With CHF; ICD9: 404.01, 404.03, 404.11; Hypertensive Heart And Renal Disease, Benign, With CHF: ICD9: 404.13; Hypertensive Heart And Renal Disease, Unspecified, With CHF: ICD9: 404.91; Hypertensive Heart + Renal Failure, Unspecified, With CHF: ICD9: 404.93; Heart Failure: ICD9: 428.xx; Congestive Heart Failure: ICD9: 428.0; Left Heart Failure: ICD9: 428.1; Systolic Heart Failure: ICD9: 428.2, 428.20, 428.21, 428.22, 428.23; Diastolic Heart Failure: ICD9: 428.3, 428.30, 428.31, 428.32, 428.33; Combined Systolic and Diastolic Heart Failure: ICD9: 428.4; Combined Systolic and Diastolic Heart Failure, unspecified: ICD9: 428.40; Combined Systolic and Diastolic Heart Failure, acute, chronic, acute or chronic: ICD9: 428.41, 428.42, 428.43; Heart Failure, unspecified: 428.9.

Step 2: Identify patients that meet age, eligibility and continuous enrollment criteria

4. Age
 - a. Identify patients 18 years and older
5. Eligibility
 - a. Identify benefits during both the identification year and the measurement year
 - b. To be included persons must have both of the following benefits in both years
 - i. Medical benefit
 - ii. Pharmacy benefit
6. Continuous enrollment
 - a. Determine enrollment during both the identification and measurement years
 - b. To be eligible, persons must have medical and pharmacy coverage for the measurement period and prior period

Step 3: Identify patients with exclusion criteria

Identify patients that meet one or more of the following exclusion criteria during the identification year: Hospitalization within 6 months prior to the measurement year with: 1) a primary diagnosis of CHF or 2) a secondary diagnosis of CHF with a primary cardiopulmonary diagnosis. The following codes are used to identify primary or secondary diagnosis of CHF (see also Table CHF-B1 and B2 in written measure specification): Rheumatic heart failure (congestive) ICD9: 398.91; Malignant Hypertensive Heart Disease with CHF: ICD0: 402.01; Benign Hypertensive Heart Disease with CHF; ICD9: 402.11; Hypertensive Heart Disease with CHF; ICD9: 402.91; Hypertensive Heart and Renal Disease, Malignant, With CHF; ICD9: 404.01, 404.03, 404.11; Hypertensive Heart And Renal Disease, Benign, With CHF: ICD9: 404.13; Hypertensive Heart And Renal Disease, Unspecified, With CHF: ICD9: 404.91; Hypertensive Heart + Renal Failure, Unspecified, With CHF: ICD9: 404.93; Congestive Heart Failure: ICD9: 428.0; Left Heart Failure: ICD9: 428.1; Systolic Heart Failure: ICD9: 428.2, 428.20, 428.21, 428.22, 428.23; Diastolic Heart Failure: ICD9: 428.3, 428.30, 428.31, 428.32, 428.33; Acute systolic heart failure: ICD9: 428.21; Acute or chronic systolic heart failure: ICD9: 428.23; Acute diastolic heart failure: ICD9: 428.31; Acute or chronic diastolic heart failure: ICD9: 428.33; Acute combined systolic & diastolic heart failure: ICD9: 428.41; Combined Systolic and Diastolic Heart Failure: ICD9: 428.4; Combined Systolic and Diastolic Heart Failure, unspecified: ICD9: 428.40; Combined Systolic and Diastolic Heart Failure, chronic: ICD9: 428.42; Heart Failure, unspecified: 428.9; Acute lung edema: ICD9: 518.4; Other symptoms involving cardiovascular system: ICD9: 785.9; Orthostatic hypotension: ICD9: 458.0; Hypotension nos: ICD9: 458.9; Abnormal cardiovascular study nos: ICD9: 794.30; Non-specific abnormal electrocardiogram: ICD9: 794.31; Abnormal cardiovascular study nec: ICD9: 794.39; Painful respiration: ICD9: 786.52; Hemoptysis: ICD9: 786.3; Cough: ICD9: 786.2; Pulmonary congestion and hypostasis: ICD9: 514; Respiratory abnormality nos: ICD9: 786.00; Hyperventilation: ICD9: 786.01; Orthopnea: ICD9: 786.02; Apnea: ICD9: 786.03; Cheyne-stokes respiration: ICD9: 786.04; Tachypnea: ICD9: 786.06; Wheezing: ICD9: 786.07; Respiratory abnormality nec: ICD9: 786.09; Other symptoms involving respiratory system and chest: ICD9: 786.9; Abnormal findings-lung field: ICD9: 793.1; Abnormal pulmonary function study: ICD9: 794.2; Cardiac dysrhythmias: ICD9: 427.xx; Paroxysmal atrial tachycardia: ICD9: 427.0; Paroxysmal ventricular tachycardia: ICD9: 427.1; Paroxysmal tachycardia nos: ICD9: 427.2; Atrial fibrillation & flutter: ICD9: 427.3; Atrial fibrillation: ICD9: 427.31; Atrial flutter: ICD9: 427.32; Ventricular flutter: ICD9: 427.42; Cardiac arrest: ICD9: 427.5; Premature beats: ICD9: 427.6; Premature beats nos: ICD9: 427.60; Atrial premature beats: ICD9: 427.61; Premature beats nec: ICD9: 427.69; Other cardiac dysrhythmias: ICD9: 427.8; Sinoatrial node dysfunc: ICD9: 427.81; Cardiac dysrhythmias nec: ICD9: 427.89; Cardiac dysrhythmia nos: ICD9: 427.9; Tachycardia nos: ICD9: 785.0; Palpitations: ICD9: 785.1; Electrolyte/fluid disorders nec: ICD9: 276.9; Hyperpotassemia: ICD9: 276.7; Hypopotassemia: ICD9: 276.8; Fluid overload: ICD9: 276.6; Abnormal blood chemistry nec: ICD9: 790.6; Abnormal coagulation profile: ICD9: 790.92; Long-term use anticoagulants: ICD9: V58.61; Shortness of breath: ICD9: 786.05; Edema: ICD9 782.3; Complicated implant cardiac defib: ICD9: 996.04; Pleurisy w/o effusion not tb: ICD9: 511.0; Pleurisy effusion nos: ICD9: 511.9; Bacterial pleurisy/effusion not tb: ICD9: 511.1; Pleural effusion nec not tb: ICD9: 511.8; Chronic respiratory failure: ICD9: 518.83; Acute and chronic respiratory failure: ICD9: 518.84; Respiratory failure: ICD9: 518.81; Other pulmonary insufficiency: ICD9: 518.82.

Eval
Rating
2a1

H
M
L
I

Eval
Rating
2b1

H
M



Identify patients that meet one or more of the following exclusion criteria during the identification OR the measurement year (see also Tables CHF-F3-F8): active cancer; ICD-9 Diagnosis: 140-171; 174-184; 187-203; 204.0; 204.2; 204.8; 205-208; 230-239 WITH CPT: 38230, 38240-38242, 77261-77799, 79000-79999, 96400-96549; ICD-9-CM Procedure: 41.0, 41.91, 92.2; UB Revenue 028x, 033x, 0342, 0344, 0973; end stage renal disease (ESRD) including renal dialysis: CPT36145, 36800-36821, 36831-36833, 90919-90921, 90923-90925, 90935, 90937, 90939, 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512; HCPCS: G0257, G0311-G0319, G0321-G0323, G0325-G0327, G0392, G0393, S9339; ICD-9-CM Diagnosis: 585.5, 585.6, V42.0, V45.1, V56; ICD-9-CM Procedure: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93, 39.94, 39.95, 54.98; UB Revenue: 080x, 082x-085x, 088x ; UB Type of Bill: 72x; POS: 65; organ transplant: CPT: 32850-32856, 33930-33945, 44132-44137, 44715-44721, 47133-47147, 48160, 48550-48556, 50300-50380; HCPCS: S2152, S2053-S2055, S2060, S2061, S2065; ICD-9-CM Procedure: 33.5, 33.6, 37.5, 41.94, 46.97, 50.5, 52.8, 55.6; UB Revenue: 0362, 0367, 0810-0813, 0819; HIV/AIDS: ICD-9 Diagnosis: 042; normal pregnancy: ICD9 Diagnosis: v22.x; ectopic pregnancy: CPT: 59120, 59121, 59130, 59135, 59136, 59140, 59150, 59151; D&C after pregnancy: CPT: 59160; Insertion of cervical dilator: CPT: 59200; Episiotomy or vaginal repair :CPT: 59300; Revision of cervix :CPT:59320, 59325; Repair of uterus: CPT: 59350; Obstetrical care: CPT: 59400, 59409,59410; Antepartum manipulation: CPT:59412; Deliver placenta:CPT:59414: Antepartum care only:CPT: 59425, 59426; Care after delivery: CPT: 59510, 59514, 59515, 59525; Vbac delivery: CPT: 59610, 59612, 59614; Attempted vbac delivery: CPT: 59618, 59620, 59622; Treatment of miscarriage:CPT: 59812, 59820, 59821; Treat uterus infection: CPT: 59830; Abortion: CPT: 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, 59866; Remove cerclage suture: CPT: 59871; Fetal invas px w/us: CPT: 59897; Lapro proc, ob care/deliver: CPT: 59898; Maternity care procedure: CPT: 59899; OB US < 14 wks: CPT: 76801, 76802; OB US >= 14 wks: CPT: 76805, 76810; OB US: CPT: 76811, 76812, 76813, 76814, 76815, 76816; transvaginal us: CPT: 76817; fetal biophys profile: CPT: 76818, 76819; Umbilical artery echo: CPT: 76820; middle cerebral artery echo: CPT: 76821; echo exam of fetal heart: CPT: 76825; Anesth: CPT: 01958, 01960,01961; Complications of pregnancy: ICD9 diagnosis: 630-676; Left ventricular assist device (LVAD): CPT: 0048T, 0049T, 33975, 33976, 33977, 33978, 33979, 33980; HCPCS: Q0491, Q0492, Q0493, Q0494, Q0495, Q0496, Q0497, Q0498, Q0499, Q0500, Q0501, Q0502, Q0503, Q0504, Q0505 ;ICD9 procedure : 37.66; Intra-aortic Balloon Pump (IABP): CPT: 33970, 33971, 33973, 33974.

Step 4: Combine prior steps to identify measure population

1. Identify CHF post hospitalization eligible population
2. Exclude those patients not meeting general inclusion criteria (e.g. age, continuous eligibility)
3. Exclude those patients meeting one or more measure exclusion criteria
4. The resulting collection of patients is the measure population

Eligible event identification:

The following codes are used to identify clinically relevant services during a CHF chronic episode.

Inpatient and outpatient events:

These codes, present in a primary or secondary diagnosis field, will be used to identify CHF-related services during the measurement period, regardless of corresponding CPT codes. The code can appear in any position on the claim. (see also Table CHF-B1-B2 in technical appendix of written measure specification): Rheumatic heart failure (congestive) ICD9: 398.91; Malignant Hypertensive Heart Disease with CHF: ICD0: 402.01; Benign Hypertensive Heart Disease with CHF; ICD9: 402.11; Hypertensive Heart Disease with CHF; ICD9: 402.91; Hypertensive Heart and Renal Disease, Malignant, With CHF; ICD9: 404.01, 404.03, 404.11; Hypertensive Heart And Renal Disease, Benign, With CHF: ICD9: 404.13; Hypertensive Heart And Renal Disease, Unspecified, With CHF: ICD9: 404.91; Hypertensive Heart + Renal Failure, Unspecified, With CHF: ICD9: 404.93; Congestive Heart Failure: ICD9: 428.0; Left Heart Failure: ICD9: 428.1; Systolic Heart Failure: ICD9: 428.2, 428.20, 428.21, 428.22, 428.23; Diastolic Heart Failure: ICD9: 428.3, 428.30, 428.31, 428.32, 428.33; Acute systolic heart failure: ICD9: 428.21; Acute or chronic systolic heart failure: ICD9:428.23; Acute diastolic heart failure: ICD9:428.31; Acute or chronic diastolic heart failure: ICD9: 428.33; Acute combined systolic & diastolic heart failure: ICD9: 428.41; Combined Systolic and Diastolic Heart Failure: ICD9: 428.4; Combined Systolic and Diastolic Heart Failure, unspecified: ICD9: 428.40; Combined Systolic and Diastolic Heart Failure, chronic: ICD9: 428.42; Heart Failure, unspecified: 428.9; Acute lung edema: ICD9: 518.4; Other symptoms involving cardiovascular system: ICD9: 785.9; Orthostatic hypotension: ICD9:458.0; Hypotension nos: ICD9:458.9; Abnormal cardiovascular study nos: ICD9: 794.30; Non-specific abnormal electrocardiogram: ICD9: 794.31; Abnormal cardiovascular study nec:ICD9: 794.39; Painful respiration: ICD9: 786.52; Hemoptysis: ICD9: 786.3; Cough: ICD9:786.2; Pulmonary congestion and hypostasis: ICD9: 514; Respiratory abnormality nos: ICD9:786.00; Hyperventilation: ICD9: 786.01; Orthopnea: ICd9: 786.02; Apnea: ICD9: 786.03; Cheyne-stokes respiration: ICD9: 786.04; Tachypnea: ICD9: 786.06; Wheezing: ICD9: 786.07; Respiratory abnormality nec: ICD9: 786.09; Other

symptoms involving respiratory system and chest: ICD9: 786.9; Abnormal findings-lung field: ICD9: 793.1; Abnormal pulmonary function study: ICD9: 794.2; Cardiac dysrhythmias: ICD9: 427.xx; Paroxysmal atrial tachycardia: ICD9: 427.0; Paroxysmal ventricular tachycardia: ICD9:427.1; Paroxysmal tachycardia nos: ICD9: 427.2; Atrial fibrillation & flutter: ICD9: 427.3; Atrial fibrillation: ICD9: 427.31; Atrial flutter: ICD9: 427.32; Ventricular flutter: ICD9: 427.42; Cardiac arrest: ICD9: 427.5; Premature beats: ICD9: 427.6; Premature beats nos: ICD9: 427.60; Atrial premature beats: ICD9: 427.61; Premature beats nec: ICD9: 427.69; Other cardiac dysrhythmias: ICD9: 427.8; Sinoatrial node dysfunct: ICD9: 427.81; Cardiac dysrhythmias nec: ICD9: 427.89; Cardiac dysrhythmia nos: ICD9: 427.9; Tachycardia nos: ICD9: 785.0; Palpitations: ICD9: 785.1; Electrolyte/fluid disorders nec: ICD9: 276.9; Hyperpotassemia: ICD9: 276.7; Hypopotassemia: ICD9: 276.8; Fluid overload: ICD9: 276.6; Abnormal blood chemistry nec: ICD9:790.6; Abnormal coagulation profile: ICD9: 790.92; Long-term use anticoagulants: ICD9: V58.61; Shortness of breath: ICD9: 786.05; Edema: ICD9 782.3; Complicated implant cardiac defib: ICD9: 996.04; Pleurisy w/o effusion not tb: ICD9: 511.0; Pleurisy effusion nos: ICD9: 511.9; Bacterial pleurisy/effusion not tb: ICD9: 511.1; Pleural effusion nec not tb: ICD9: 511.8; Chronic respiratory failure: ICD9: 518.83; Acute and chronic respiratory failure: ICD9: 518.84; Respiratory failure: ICD9: 518.81; Other pulmonary insufficiency: ICD9: 518.82.

The following codes will be used to help identify those services that should be categorized as “E&M” during the analyses. Such services, when present in the identification (pre-measurement) period, are used to identify patients for the measure’s denominator. When present during the measurement period, these services are counted to determine the provider or providers to whom the episode will be attributed (see also Table CHF B3). General physician office visits: CPT: 99201-99205, 99211-99215; preventive medicine screening: CPT: 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99384-99387; observation care: CPT: 99217-99220; emergency dept care: CPT: 99281-99285; home health: CPT: 99341-99345, 99347-99350; skilled nursing facility: CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337; office consultation: CPT: 99241-99245; unlisted: CPT: 99455, 99456.

Procedures and laboratory

The following procedure codes will be used to identify CHF-related services during the measurement period, regardless of corresponding ICD-9 diagnosis codes. Codes may appear in any position on the claim (see also Table CHF-C): cholesterol: CPT: 80061, 83700, 83701, 83704, 83718, 83719, 83721; BNP blood test: CPT: 83880; Cardiac catheterization: CPT: 93501, 93503, 93510, 93511, 93514, 93524, 93526, 93527, 93528, 93529, 93539, 93540, 93555, 93556; chest x-ray: CPT: 71010, 71015, 71020, 71021, 71022, 71023, 71030, 71034, 71035, 75756, 93542, 93543, 93545; Coronary angiography, Computed tomographic angiography, Cardiac MRI: CPT: 71275, 75635, 75898, 93508, 75552, 75553, 75554, 75555, 75556, 75557, 75558, 75559, 75560, 75561, 75562, 75563, 75564, 76390; HCPCs: 0144T, 0145T, 0146T, 0147T, 0148T, 0149T, 0150T, 0151T; Echocardiogram: CPT: 93303, 93304, 93306, 93307, 93308, 93312, 93313, 93314, 93315, 93318, 93320, 93321, 93325, 93350, 93351, 93352; HCPCs: A9900; Electrocardiogram (ECG or EKG): CPT: 93000, 93005, 93010, 93012, 93014, 93040, 93041, 93042, 93270, 93272, 93278 ; Exercise stress test (cardiac stress test): CPT: 93015, 93016, 93017, 93018; Holter monitor: CPT: 93224, 93225, 93226, 93227, 93230, 93231, 93232, 93236, 93237; 93224, 93225, 93226, 93227, 93230, 93231, 93232, 93236, 93237; Nuclear heart scan (Stress Thallium): CPT: 78414, 78428, 78460, 78461, 78464, 78465, 78466, 78468, 78472, 78473, 78478, 78480, 78481, 78483, 78494, 78496, 78499, 78469, 78459, 78491, 78492; HPCPs: A9502, A9505; Pharmacologic Stress Test: CPT: 93024; Cardiac output measurement: CPT: 93561, 93562; Heart flow reserve measure: CPT: 93571, 93572; Pacemaker, Cardioverter defibrillator: CPT: 93745, 93741, 93742, 93743, 93744, 93745, 93282, 93283, 93284, 93287, 93289, 93295, 93296, 33216, 33217, 33224, 33225, 33215, 33220, 33240, 33245, 33249; HCPCs: K0606, K0607, K0608, K0609, G0297, G0298, G0299, G0300; injections: HCPCs: C9109, C9121, J0130, J0350, J0583, J1160, J1162, J1245, J1250, J1327, J1642, J1644, J1645, J1650, J1652, J1655, J2260, J2324, J2325, J3245, J3246, J3265

Prescription drugs

The episode includes the following medications by therapeutic class or generic brand: Ace inhibitors: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril; angiotension II inhibitors: candesartan, irbesartan; olmesartan, valsartan, eprosartan, losartan, telmisartan; diuretics, vasodilators, digoxin, beta blockers: metoprolol, carvedilol, bisoprolol; anticoagulants: warfarin, heparin, statins, calcium channel blockers, inotropes: dobutamine, milrinone; antiplatelets, CoQ10, atorcure, cardiac drugs, NEC

Durable Medical Equipment

The following procedure codes will be used to identify CHF-related services during the measurement period, regardless of corresponding ICD-9 diagnosis codes. Codes may appear in any position on the claim (see also Table CHF-E): Oxygen therapy rx: HCPCs: 4030F; C-PAP: HCPCs: E0601, E0601, A7034, A7032, A7030, A7031, A7044, A7046, A7037, A7038, A7039, A7035, A7033, A7036, E0561, E0562, E0470, KO532

Rationale for cluster, grouping and assignment

Age: The measure includes individuals 18 years of age or older at the time of the qualifying event. Those younger than 18 years of age were excluded because the disease does not typically occur in that group and therefore they were not considered a meaningful group to include in the measure.

Two ambulatory visits: To be included in the measure, an individual must have had at least two ambulatory care visits for CHF with one at least one month before the measurement period. This measure seeks to examine individuals in a stable chronic management phase of the condition. Having at least one ambulatory visit one month before the measurement period was to ensure that individuals in the measure do not have new onset of CHF, which would be a less homogenous group who would be likely to have a different healthcare utilization and cost pattern.

Exclusion of individuals with prior hospitalization: Individuals were excluded if they had a hospitalization within 6 months prior to the measurement year with 1) a primary diagnosis of CHF or 2) a secondary diagnosis of CHF with a primary cardiopulmonary diagnosis. This exclusion is to create a more homogenous patient group for this measure. Patients with a hospitalization may be less likely to be in a stable management phase of the condition.

Standard exclusions: We have several standard exclusions for each of our measures that are similar to the NCQA exclusions for their relative resource use measures. We exclude individuals with high resource use and high cost conditions that would likely be systematically different from the majority of individuals included in the analysis. These individuals are excluded to create a more homogeneous population included in the analysis.

Exclusion of left ventricular assist device (LVAD) and mechanical assist devices: Individuals with these devices may have greater healthcare needs and as a result including these individuals would create a less homogeneous patient group.

Diagnostic codes to identify patients with CHF: Diagnostic codes to identify individuals with CHF were based on work by Prometheus. We did not want to include trigger diagnoses for the chronic CHF measure that were for hospitalizations or acute flare-up of CHF. Therefore, acute systolic heart failure (ICD-9: 428.21), acute on chronic systolic heart failure (ICD-9: 428.23), acute diastolic heart failure (ICD-9: 428.31), acute on chronic diastolic heart failure (ICD-9: 428.33), acute combined systolic & diastolic heart failure (ICD-9: 428.41), acute chronic combined systolic & diastolic heart failure (ICD-9: 428.43), and acute lung edema (ICD-9: 518.4) are CHF-related codes that were not included as trigger diagnoses to identify the cohort; however, these codes are used to identify CHF-related healthcare utilization during the measurement period.

Rationale for assignment of specified codes:

The scope of this measure was focused on one year of care for individuals with CHF so that this measure can ultimately be paired with quality measures. Each of the codes included in the lists were considered to be related to CHF care during the one-year measurement period by the CHF clinical workgroup because these codes were CHF or cardiopulmonary-related. An initial list of diagnostic codes for CHF and cardiopulmonary conditions were based on work by Prometheus (1). Subsequently, the CHF workgroup determined which of these codes were relevant for the episode of care measure using a quasi-Modified Delphi Approach. Moreover, during the measurement testing and validation process, the CHF workgroup refined the diagnostic codes, procedure codes, and medications included the episode of care measure.

The overarching rationale for each of the codes included in the list is that the clinical workgroup considered the codes as potentially associated with the care of chronic CHF. Importantly, this was not limited to appropriate care, but rather focused on resources that were likely to be associated with the condition.

The diagnostic codes selected as related to the episode include those for identifying patients with CHF and any subsequent CHF or cardiopulmonary care related to the management of chronic CHF. Each of the diagnostic codes identifies resources grouped to the episode if the code is present in any diagnosis field.

The following provides the rationale for the codes included in the chronic CHF measure. The heart failure codes used to identify individuals for inclusion in the measure are also used to identify CHF-related care during the measurement year. In addition, acute systolic heart failure (ICD-9: 428.21), acute on chronic systolic heart failure (ICD-9: 428.23), acute diastolic heart failure (ICD-9: 428.31), acute on chronic diastolic heart failure (ICD-9: 428.33), acute combined systolic & diastolic heart failure (ICD-9: 428.41), acute chronic combined systolic & diastolic heart failure (ICD-9: 428.43), and acute lung edema (ICD-9: 518.4) are CHF-related codes that were not included as trigger diagnoses to identify the cohort; however, these codes are used to identify CHF-related healthcare utilization during the measurement period.

Pulmonary complications of heart failure include loss of surfactant, increased pulmonary dry weight and reduced lung volume (2). Consequently, we have also included pulmonary codes to assess care associated with CHF (e.g., painful respiration [ICD-9: 786.52], hemoptysis [ICD-9: 786.3], cough [ICD-9: 786.2], shortness of breath [ICD-9: 786.05], pulmonary congestion and hypostasis [ICD-9: 514], dyspnea and respiratory abnormalities [ICD-9: 786.xx]) as well as

durable medical equipment for oxygen therapy and C-PAP. Electrolyte and fluid disorders were included in the measure because electrolyte disturbances are a common complication of CHF (e.g., hyperpotassemia [ICD-9:276.7], hypopotassemia [ICD-9:276.8], fluid overload [ICD-9:276.6])(3). Codes for dysrhythmia (e.g., cardiac dysrhythmias [ICD-9: 427.xx]), which are a common cause of cardiovascular hospitalizations (4), were included in the measure. Moreover, atrial fibrillation as well as edema have been associated with longer lengths of hospitalization in individuals with CHF (5). CHF is traditionally associated with increased risk of thromboembolic complications (6). Consequently, care related to coagulation has also been included in the measure (e.g., long-term use anticoagulants [ICD-9: V58.61], abnormal coagulation profile [ICD-9: 790.92]).

Elevated LDL and coronary atherosclerosis are risk factors for heart disease and development of CHF, and codes to assess care for these are included. Brain natriuretic peptide (BNP) is a natriuretic hormone released primarily from the heart. It is useful in distinguishing CHF due to systolic and/or diastolic dysfunction from other causes of dyspnea. Chest x-rays are a useful diagnostic test, particularly in the evaluation of patients who present with dyspnea, to differentiate CHF from primary pulmonary disease (7). Echocardiography provides important information about ventricular size and function (8). Electrocardiograms may show findings that can suggest specific causes of CHF and can also detect arrhythmias, which may cause or exacerbate CHF. Stress testing is helpful in detection of ischemic heart disease and the need for coronary arteriography. The extent of coronary disease as determined by angiography contributes more prognostic information than the clinical diagnosis of ischemic cardiomyopathy alone (9). Cardiovascular magnetic resonance (CMR) imaging can be used to identify late myocardial enhancement and to identify coronary artery disease or different types of cardiomyopathy. The Holter monitor can detect different arrhythmias that can induce or exacerbate CHF. An implantable cardioverter-defibrillator is used for secondary prevention of sudden cardiac death and for primary prevention in selected individuals with CHF.

Several major societies have published extensive guidelines for the treatment of CHF(10-13). The medications selected for inclusion in the measure met at least one of the following criteria:

- Used in the management of chronic, stable CHF.
- Used to treat symptoms that may be associated with CHF.
- Used to treat acute exacerbations of CHF.
- Used to reduce the risk of recurrence of exacerbations.
- Used to treat dyslipidemia.

References:

1. <http://www.prometheuspayment.org/>
2. Kee K, Naughton MT. Heart failure and sleep-disordered breathing: mechanisms, consequences and treatment. *Curr Opin Pulm Med*. 2009 Aug 26.
3. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia *Am Heart J*. 1994 Sep;128(3):564-74.
4. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. *Clin Cardiol*. 2010 May;33(5):270-9.
5. Krumholz HM, Chen YT, Bradford WD, Cerese J. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. *Am J Manag Care*. 1999 Jun;5(6):715-23.
6. Dotsenko O, Kakkar VV. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. *J Thromb Haemost*. 2007 Feb;5(2):224-31
7. Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? *J Gen Intern Med* 1996; 11:625.
8. Erbel R, Schweizer P, Krebs W, et al. Sensitivity and specificity of two-dimensional echocardiography in detection of impaired left ventricular function. *Eur Heart J* 1984; 5:477.
9. Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. *J Am Coll Cardiol* 1997; 30:1002.
10. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009; 119:e391.
11. Dickstei, K, Cohen-Sola, A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008; 29:2388.
12. Arnold, JM, Liu, P, Demers, C, et al. Canadian Cardiovascular Society consensus conference recommendations on

heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23
 13. Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12:10.

S8.3. Comorbid and interactions

Detail the treatment of co-morbidities & disease interactions and provide rationale for this methodology.

see risk adjustment details in Section S10.1 below

S8.4. Clinical hierarchies

Detail the hierarchy for codes or condition groups used and provide rationale for this methodology.

The only clinical hierarchies used in the measure are associated with the identification of comorbid conditions that are used in risk adjustment. Details are provided in Section 10.1 below and in the risk adjustment section of the technical appendix of the written measure specification. In short, we use the CMS hierarchical condition categories (HCC) for assignment of comorbid conditions which utilizes a hierarchy of codes based on the ICD-9 codes present during the pre-index period. We rely on the HCC system for identifying comorbid conditions in our risk adjustment procedure. The hierarchies are important for our risk adjustment as they are intended to identify different levels of severity of conditions that may be differentially associated with resource use. We used the HCC system because it is a previously developed and validated system for use in resource use measures.

Within our episode measure there are no hierarchies assigned to any of the codes that use.

S8.5. Clinical severity levels

Detail the method used for assigning severity level and provide rationale for this methodology.

We do not provide specifications for clinical severity levels.

No severity level is defined for patients included in the episode. We attempt to create a relatively homogenous population through our inclusion and exclusion criteria.

S8.6. Concurrency of clinical events (that may lead to a distinct measure)

Detail the method used for identifying concurrent clinical events, how to manage them, and provide the rationale for this methodology.

We do not provide specifications for concurrency of clinical events.

Each of the measures developed as part of the ABMS measure set was intended as a standalone measure. The measures were not designed to be combined into a single composite measure of resource use for providers. Because the focus during the development of these measures was there eventual pairing with quality measures, each of the measures is considered as a unique measure. Therefore, the concurrency of events and the fact that events may be counted in more than one measure is not an issue. We were not trying to account for the overall resource use of a population but rather focused on resource use within specific cohorts of patients. The relative resource information produced is intended to result in actionable information which is not possible when all of the episodes are combined into a single composite measure.

S9. Measure Construction Logic (Resource Use Measure Module 3)

The measure's construction logic includes steps used to cluster, group or assign claims beyond those associated with the measure's clinical logic. For example, any temporal or spatial (i.e., setting of care) parameters used to determine if a particular diagnosis or event qualifies for the measure of interest.

Construction Logic Supplemental Attachment or URL:

If needed, attach supplemental documentation (Save file as: S9_Construction Logic). All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.)

URL: <http://www.healthqualityalliance.org/hvhc-project/cost-care-measurement-development>
 Please supply the username and password:
 Attachment:

S9.1. Brief Description of Construction Logic
Briefly describe the measure's construction logic.

The following sequence is used to construct the measures:

1. Eligible population identification
2. Identification of related resources
3. Assignment of standardized prices
4. Creation of episode specific strata (if applicable)

S9.2. Construction Logic

Detail logic steps used to cluster, group or assign claims beyond those associated with the measure's clinical logic.

The following steps are used to complete the construction sequence (for specific codes, see Section S8.2 clinical framework and written measure specification/technical appendix accessed via the URL).

The measurement period of this episode is 12 months in duration preceded by a 12 month identification period. For convenience, users may choose a calendar year with a start of Jan 1 and an end of Dec 31. However, if the user has a dataset that closes on a different time frame (i.e. it isn't built on a calendar year), they should use date ranges that are easiest to implement.

Eligible population identification

Step 1: Identify patients that meet the following criteria during the identification and measurement years: Two ambulatory visits for CHF-related care with at least one visit > 1 month prior to the measurement year (see Table CHF-A)

Step 2: Identify patients that meet age, eligibility and continuous enrollment criteria. Age: Identify patients 18 years and older. Eligibility : Identify benefits during both the identification year and the measurement year. To be included persons must have both of the following benefits in both years: Medical benefit, Pharmacy benefit. Continuous enrollment: Determine enrollment during both the identification and measurement years. To be eligible, persons must have medical and pharmacy coverage for the measurement period and prior period (do not include persons whose pharmacy benefits are dropped partway through the identification or measurement period).

Step 3: Identify patients that meet one or more exclusion criteria during the identification year: Hospitalization within 6 months prior to the measurement year with: 1) a primary diagnosis of CHF (Table CHF-B1) or 2) a secondary diagnosis of CHF with a primary cardiopulmonary diagnosis (Table CHF-B2). Also identify patients that meet one or more of the following exclusion criteria during the identification OR the measurement year (Tables CHF-F3 – CHF-F8): Active cancer treatment, ESRD, organ transplant, HIV/AIDs, pregnancy, Left ventricular assist device (LVAD), intra-aortic balloon pump.

Step 4: Combine prior steps to identify measure population: 1) Identify CHF eligible population. 2) Exclude those patients not meeting general inclusion criteria (e.g. age, continuous eligibility 3) Exclude those patients meeting one or more measure exclusion criteria, 4) The resulting collection of patients is the measure population

Eligible event identification

For each individual in the measure population, identify the following paid claims for services rendered during the measurement year. Claims / encounters will be identified based on the presence of CHF -related or cardiopulmonary-related diagnosis codes or procedure codes. These events will be used to determine the related resource use.

Inpatient and Outpatient events: Identify all inpatient and outpatient claims / encounters with a CHF-related (see Table CHF-B1) or cardiopulmonary-related (see Table CHF-B2) diagnostic code appearing in any position.

Procedures and laboratory: Identify all claims / encounters with one of the following CPT or HCPCs codes (see Table CHF-C). These procedure codes will be used to identify CHF-related services during the measurement period, regardless of corresponding ICD-9 diagnosis codes.

Prescription drugs: Identify the following medications by therapeutic class or generic/brand medication name during the

measurement period (See Table CHF-D):
 Durable medical equipment: Identify all claims / encounters with one of the following HCPCs codes (see Table CHF-E) to identify durable medical equipment.

Assignment of standardized prices

Standardized prices are calculated for all of the components of care used to treat or manage the patient’s condition to ensure that comparisons can be made solely on the basis of differential practice patterns and resource use. Three separate methodologies are used to derive these standardized prices: for inpatient facility charges, for ambulatory pharmacy charges (i.e., prescriptions dispensed outside the inpatient hospital setting), and for all other charges. These standardized prices are then applied to the claims identified as CHF-related. For further information on standardized price methods, see section S10.3 below.

Creation of episode specific strata

not applicable

S9.3. Measure Trigger and End mechanisms

Detail the measure’s trigger and end mechanisms and provide rationale for this methodology.

Because patients with new onset of CHF and/or unstable CHF may have more intensive healthcare needs, this episode of care measure is focused on patients with stable CHF in a management phase of this condition. To identify patients in a management phase of CHF, the expert panel of clinicians in the CHF workgroup specified that patients be required to have two ambulatory visits for CHF. To ensure that patients assessed by this episode of care measure do not have new onset CHF, at least one of these ambulatory visits must be more than 1 month prior to the measurement period.

Due to chronic nature of this condition, we selected 1 year timeframe for measurement (in keeping with the convention used for many other measures of chronic conditions). In order to identify a more homogeneous population, triggers/eligible population are identified in the year prior to measurement year.

For convenience, users may choose a calendar year with a start of Jan 1 and an end of Dec 31. However, if the user has a dataset that closes on a different time frame (i.e. it isn’t built on a calendar year), they should use date ranges that are easiest to implement.

S9.4.Measure redundancy or overlap

Detail how redundancy and overlap of measures can be addressed and provide rationale for this methodology.

We do not provide specifications for measure redundancy or overlap.

To avoid redundancy and overlap within episodes of congestive heart failure, we have elected to create two distinct measures. One measure for chronic CHF and a separate measure for CHF post-hospitalization. There is no overlap between the two measures.

Beyond CHF, the measures developed by ABMS REF were developed as standalone measures to address all relevant services associated with a particular health care condition. collectively, the measures do not sum-up to a single total and there is the potential for overlap and redundancy to occur when multiple measures are applied simultaneously.

S9.5.Complementary services

Detail how complementary services have been linked to the measure and provide rationale for this methodology.

We do not provide specifications for linking complementary services.

All services included in the measure are included based on the presence of diagnosis codes, procedure codes, or medications.

Services are identified based on presence of qualifying codes. There is no effort to link complementary services to the episode. The strategy for all of our measures was to rely on the presence of codes to qualify for inclusion in the episode rather than to make assumptions about temporal or other associations between events.

S9.6.Resource Use Service Categories

Inpatient services: Inpatient facility services
 Inpatient services: Evaluation and management
 Inpatient services: Procedures and surgeries
 Inpatient services: Imaging and diagnostic
 Inpatient services: Lab services
 Inpatient services: Admissions/discharges
 Ambulatory services: Outpatient facility services
 Ambulatory services: Emergency Department
 Ambulatory services: Pharmacy
 Ambulatory services: Evaluation and management
 Ambulatory services: Procedures and surgeries
 Ambulatory services: Imaging and diagnostic
 Ambulatory services: Lab services
 Durable Medical Equipment (DME)

S9.7. Identification of Resource Use Service Categories

For each of the resource use service categories selected above, provide the rationale for their selection and detail the method or algorithms to identify resource units, including codes, logic and definitions.

At the claim line level, the user should identify all relevant codes specified in the clinical framework Section 8.2 above (see also written measure specification). For inpatient services, these include all relevant ICD9, DRG v24, DRGv25, CPT codes; for ambulatory services, these include all relevant ICD9, and CPT codes; for procedures and laboratory these include all relevant ICD9 procedure codes, HCPCs, and CPT codes, and for prescription drugs, these include relevant HCPCs and NDCs.

The above categories were selected because they represent the vast majority of resource use for the episode and the measure developers examined the distribution of costs between categories to evaluate the face validity of the measure. Developers also reasoned that resource use variation between providers by category would be informative. Please refer to Section S8.2 Clinical Framework for the algorithms used to identify/assign some services.

Measure developers also applied the Berenson-Eggers Types of Service (BETOS) system which categorizes all HCPCS codes into resource use areas (e.g. Evaluation and Management, Procedures, Imaging, etc). In addition to the BETOS category there is an additional category included for medications related resource use that is determined using pharmacy data and HCPCS.

Rationale: The BETOS classification system is a widely used, publically available system for classifying healthcare services. These categories can be used to examine cost patterns across providers to identify differences across the different categories of service. This system provides a sufficient number of categories to make meaningful comparisons across patterns of resource use and yet is not too broad so as not to be able to draw conclusions based on differences. Furthermore, identification of important differences allows users to drill down within those categories to identify cost drivers within BETOS categories that may ultimately provide actionable information for providers.

If needed, provide specifications URL (preferred) or as an attachment:

URL:
 Please supply the username and password:
 Attachment:

S9.8. Care Setting; provides information on which care settings the measure encompasses.

Ambulatory Care : Ambulatory Surgery Center (ASC)
 Ambulatory Care : Clinic/Urgent Care
 Ambulatory Care : Clinician Office

Hospital/Acute Care Facility
 Imaging Facility
 Laboratory
 Pharmacy

S10. Adjustments for Comparability (Resource Use Measure Module 4)
External factors can mingle and affect or confound a measure's result. Confounding occurs if an extraneous factor causes or influences the outcome (e.g., higher resource use) and is associated with the exposure of interest (e.g., episode of diabetes with multiple co-morbidities). Measure developers often include steps to adjust the measure to increase comparability of results among providers, employers, and health plans.

S10.1. Risk adjustment method
Define risk adjustment variables and describe the conceptual, statistical, or other relevant aspects of the model and provide rationale for this methodology.

Calculation of risk adjusted costs (see also the risk adjustment section in the technical appendix of the written measure specification).

The risk adjustment models were developed and tested on the same population used for the measure testing—the Thomson Reuters Healthcare MarketScan database, with over 30 million covered lives in each year.

The sample size for the chronic congestive heart failure episode was: 11,494

The models were developed using a split sample approach with 75% of the cohort used in the development phase and 25% used to evaluate the model fit. In addition, model fit was also evaluated in the entire cohort.

The model developed for comorbidity adjustment uses Hierarchical Condition Categories (HCC) to identify comorbidities. This reflects the risk adjustment methodology used by CMS and recently evaluated by NCQA for their Relative Resource Use (RRU) measures. However, there is an important distinction between the use of HCCs by CMS and the model evaluated by NCQA and the risk adjustment model used to estimate expected costs. The CMS and NCQA model use HCCs to adjust TOTAL costs of care, whereas this model focuses on episode-specific costs of care. Because models developed to adjust total costs of care may not reflect the expected costs for episode-specific resource use, new models were developed from a sample of commercially insured patients for risk adjustment. The following process was completed to develop the models:

1. Utilized quasi-Modified Delphi approach with the condition-specific workgroup to categorize HCCs into three groups:

- Include in risk adjustment model;
- Exclude in risk adjustment model; and
- Test impact in risk adjustment model.

2. Identified HCCs in denominator population during the 12 months preceding the measurement year.

3. Tested 12 different model specifications (see Table CHF-RA1 in technical appendix of written measure specification), where the HCCs included in the model varied, and the distribution and link functions in the generalized linear models also varied. Models were developed in a stepwise manner as indicated. The first four models used a gamma distribution and a log link function. The first model included all HCCs identified by the condition-specific workgroup as “Include HCCs” with a prevalence in the population of $\geq 1\%$. The second model was a reduction of the first model that only included HCCs where $p < 0.1$. The third model extended the second model by including HCCs with prevalence $\geq 1\%$ identified as “Test HCCs” by the condition-specific workgroup. The fourth model was a reduction of the third model and included only those HCCs where $p < 0.1$. The next set of four models (Models 5-8) repeated the process of the first four models but used a normal distribution and identity link function. Model 9 used all of the HCCs, with the exception of the HCC for the episode being evaluated (e.g., heart failure for the CHF episode), and a gamma distribution with log link function. Model 10 was a reduction of Model 9 where only the HCCs with $p < 0.1$ were included. The final two models (Models 11-12) used the same process as Models 9 and 10 with a normal distribution and identity link function.

4. Models were developed in a split sample approach with 75% of the population randomly selected for model development and the remaining 25% used in model evaluation. Model performance was also evaluated in the full

cohort.

5. The performance of each model was evaluated through comparisons of the observed and predicted distributions, comparisons of residuals, comparisons of absolute differences between observed and predicted, comparisons of observed-to-predicted ratios, and comparisons of mean squared errors across models. Summary information on model performance was presented to the condition-specific workgroup for selection of a risk adjustment model for the condition. Final model selection was based on the best performing model across metrics. Where model performance was similar, models using the normal distribution were preferentially chosen over the gamma distribution models for ease of implementation. More parsimonious models were also preferentially chosen.

The following is the model selected for estimating adjusted costs in the CHF episode.

Risk Adjustment Model

Risk Adjusted CHF Episode Costs = $2390 + (\text{Male} * 376) + (\text{Diabetes with renal or peripheral circulatory manifestation} * 1850) + (\text{Unstable angina or other acute ischemic heart disease} * 1548) + (\text{Angina pectoris; old myocardial infarction} * 599) + (\text{Cardio-respiratory failure and shock} * 3054) + (\text{Major complications of medical care and trauma} * 2741) + (\text{Specified heart arrhythmias} * 2194) + (\text{Diabetes with neurologic or other specified manifestation} * 2161) + (\text{Acute myocardial infarction} * 1163) + (\text{Chronic obstructive pulmonary disease} * 1370)$

Measure implementers have two choices when calculating risk adjusted costs. The first is to follow the process specified above to create risk adjustment models that are specific to their population and their dataset. The second option is to follow the below steps and use the above estimates for calculating risk adjusted costs. While the latter is a straightforward calculation, caution is warranted as the risk adjusted equations were derived from a population that may be different from the population to which the measure is being applied.

To estimate risk adjusted costs using the above risk adjustment equations in the measurement population, use the following steps:

Step 1: Identify the presence of HCCs on any claim in the 12 months preceding the measurement year, utilizing both inpatient (primary diagnosis field only) and outpatient encounters (all diagnosis fields).

Step 2: Create a person level file that contains an indicator (yes/no) variable for each of the HCCs. These variables indicate whether or not the patient had evidence of each HCC during the previous 12 months.

Step 3: Calculate an adjustment factor of the average episode costs in the measure population and divide it by the average cost of the test episode (Table CHF-RA2). Apply the inflation factor to the risk adjustment coefficients to account for cost differences between datasets used in development of the risk adjustment models and those used in calculating episode costs.

Summary estimates of the average cost for the CHF episode in the test episode: Average Cost: \$3,511

Example: To calculate the inflation factor, determine the average episode cost for the population to which the measure is being applied. As an example, the average cost might be \$4,200. Calculate the adjustment factor by dividing the costs from the current population by the average cost of \$3,511. That would result in an adjustment factor of 1.20 ($4,200/3,511 = 1.20$). The adjustment factor is then applied to the estimated coefficients for the adjusted risk adjustment model.

Risk Adjusted Model

Risk and Mean Adjusted CHF Chronic Episode Costs = $1.20 * \text{Risk Adjusted CHF Episode Costs}$

Step 4: Use the equation for the appropriate age group to generate risk adjusted expected costs for each individual in the dataset.

Comorbidity Adjustment Strategy Rationale:

We acknowledge that risk adjustment is an important part of the development of an episode of care measure. Risk adjustment is intended to account for variation in episode costs that are not due to differences in practice patterns but rather are due to differences in the case mix of patients. When reporting episode costs at the provider level, risk

adjustment attempts to account for differences in the case mix of patients across providers and minimizes the assertion that one providers patients are sicker than the comparator patients. An additional advantage of episode-based measurement is that focusing on costs related to care only for that episode may be a form of risk adjustment because we are not looking at the overall healthcare costs of the patients. Our risk adjustment strategy was not to attempt to account for all of the variation within an episode; however we want to be able to control for resource use variation that is attributed to the episode that may result from differences in patient case mix.

We selected to use Hierarchical Condition Categories (HCC) as our primary strategy for identification of comorbid conditions and for risk adjustment. We selected HCCs because of their use in risk adjustment methodology used by CMS and recently evaluated by NCQA for their Relative Resource Use (RRU) measures. We felt that many users of our episodes would be familiar with HCCs and the use of these measures in administrative data. Moreover, the analytic programmers for generating HCCs are freely available on the CMS website and therefore we mitigate issues of access to code for creating the risk adjustment groups.

While we use HCC as the starting point for our risk adjustment models, there is an important distinction between the use of HCCs by CMS and the model evaluated by NCQA and our episode definitions. The CMS and NCQA model use HCCs to adjust for TOTAL costs of care whereas, we are focused on the episode-specific costs of care. Briefly, NCQA has created weights for each of the HCCs on total costs of care using data from a large population that has one of the conditions in their RRU measure. These weights can then be applied to different populations to adjust for the presence of comorbid conditions when estimating total costs. The primary concern with applying the adjustment factors available from either CMS or NCQA are the fact they are total costs and not related to the episode-specific costs of care. This would lead to very different risk adjustment models that would not account for as much of the variability within the episode as a risk adjustment model focused on episode-specific costs. We compared the use of the 'off the shelf' HCC values with a risk adjustment model developed specifically for our episode.

See attached supplemental document for illustrative example of comparison of "off the shelf" HCC values to the risk adjustment model developed specifically for our episode (note: diabetes is used for purposes of illustration).

Given the disparity in the means and distributions of the off the shelf HCC values, we felt this justified our approach to develop risk adjustment models for each of our episodes that were focused on episode specific costs.

If needed, provide supplemental information via a web URL (preferred) or attachment with the risk adjustment specifications.

URL:

Please supply the username and password:

Attachment: 10.1_Risk adjustment method-634339238228454379.pdf

S10.2. Stratification Method

Detail the stratification method including all variables, codes, logic or definitions required to stratify the measure and rationale for this methodology

This method is not stratified.

S10.3. Costing Method

Detail the costing method including the source of cost information, steps to capture, apply or estimate cost information, and provide rationale for this methodology.

Standardized prices are calculated for all of the components of care used to treat or manage the patient's condition to ensure that comparisons can be made solely on the basis of differential practice patterns and resource use. Three separate methodologies are used to derive these standardized prices: for inpatient facility charges, for ambulatory pharmacy charges (i.e., prescriptions dispensed outside the inpatient hospital setting), and for all other charges. These standardized prices are then applied to the claims identified as related.

Standard Cost Calculation

Step 1 Identify all claims paid for services rendered during the measurement period and with positive non-zero paid amounts for all patients, regardless as to whether they have been included in the measure population (rejected or unadjudicated claims should be dropped). Categorize these claims as follows (in accordance with the BETOS classification process):

- Inpatient Facility (services provided by a facility during an acute inpatient hospital stay, standard price includes room and board and ancillary services)
- Ambulatory Pharmacy (ambulatory prescriptions included in a member’s pharmacy benefit)
- All other (E&M, procedures, imaging, tests, DME, other, and exceptions/unclassified)

Step 2 For each category identified, compute standardized prices. Refer to each service category’s instructions (i.e., Calculating Standard Units of Service and Total Standard Cost) below.

Step 3 Combine standardized prices with eligible events (e.g., through a file merge as specified in each service category’s instructions).

Step 4 For each individual claim, multiply the standardized price by the number of service units identified on the claim to determine the full cost of the service, hospitalization, or prescription.

Calculating Standard Units of Service and Total Standard Cost: Inpatient Facility

For inpatient facility costs, standardized prices are developed at the diagnosis-related group (DRG) level and – for those hospitalizations where DRG-level information is unavailable – at the ADSC level. Each is adjusted for length-of-stay (LOS) so as to more closely mirror the payment systems typically applied among commercial health plans. Both approaches use RRU HEDIS standardized daily price tables developed by NCQA. All inpatient facility costs are considered “acute” for this analysis.

Step 1 Identify all inpatient stays that occurred during the measurement period. Include stays that may have started before the measurement period or ended after the close of the measurement period. Define a single, unique record describing the member’s inpatient stay.

Step 2. Identify the primary discharge DRG. Also identify the DRG version (e.g., CMS-DRG vs. MS-DRG). Care must be taken in using the standardized price tables (specified below) to insure the data and the tables use the same DRG version.

Step 3 Compute the stay’s total LOS in days, using paid or expected-to-be-paid days only. Include all paid days in the LOS calculation, whether or not they fall outside the measurement period. Also identify the stay’s LOS group based on the stay’s LOS and the information below.

LOS (Days)	LOS GRP
1	A
2	B
3-4	C
5-6	D
7-8	E
9-15	F
16 or more	G

Step 4 Compute the LOS per diem multiplier. If the inpatient stay falls completely within the measurement period, use the total number of paid days as the per diem multiplier. If the inpatient stay does not fall completely inside the measurement period, count only the days within the measurement period (including the last day of the period) to compute the per diem multiplier.

Step 5 Download the HEDIS RRU standardized daily price tables from the NCQA website (<http://www.ncqa.org/tabid/1092/Default.aspx>) for the corresponding measurement periods. Note that there is a one period lag in the file and data periods (i.e. files designated 2007 are based on 2006 data). Some periods may have two sets of tables if there is a significant change in DRG versions. Note: The project staff worked in collaboration with NCQA in development of this methodology for purposes of testing the initial set of measures. Users of the measures may wish to implement their own methodology that does not rely on a price list from NCQA.

Step 6 Calculate the DRG-specific per-diem payment rate by adjusting the standard daily prices for inflation to a reference period using the medical care component of the Consumer Price Index (CPI).

Step 7 Combine DRG-specific per-diem payment rates with the dataset containing eligible inpatient hospital events for the measure. For each event, multiply the per-diem payment rate by the event's LOS per diem multiplier to determine the event's total standard cost.

Total standard costs will not be computed using this approach for stays that have not been assigned a DRG, and for DRGs that are not assigned a standard price by HEDIS. These stays will be assigned a standard price using the ADSC method described below. (Note: Figures presented in this example are arbitrary and do not reflect any particular dataset or patient. Additionally, the DRG XXX is intended to be used as an illustrative example for calculating inpatient costs. Only DRGs related to the episode should be included in this calculation).

Example:

Assume the calculated DRG-specific per-diem payment rate for DRG XXX for FY 2007 is \$900.17. An eligible member had an inpatient stay with the following characteristics:

- A principal diagnosis with an eligible ICD-9 code
- A DRG of XXX (DRG associated with an eligible inpatient stay for the episode)
- Date of admission of February 2, 2007 and date of discharge of February 9, 2007 (fiscal period 2007)
- A LOS of 8 days, and therefore a LOS per diem multiplier of 8 days

This event has a calculated total standard cost of $\$900.17 \times 8 = \$7,201.36$.

Example:

Again assume the calculated DRG-specific per-diem payment rate for DRG XXX for FY 2007 is \$900.17. An eligible member had an inpatient stay with the following characteristics:

- A principal diagnosis with an eligible ICD-9 code
- A DRG of XXX (DRG associated with an eligible inpatient stay for the episode)
- Date of admission of December 28, 2006 and date of discharge of January 2, 2007 (fiscal period 2007)
- A LOS of 6 days, and a LOS per diem multiplier of 2 days (January 1-2).

This event has a calculated total standard cost of $\$900.17 \times 2 = \$1,800.34$.

Step 8 If DRG information is not available for a given inpatient hospitalization a method must be used that assigns prices to those hospitalizations. The methodology used in testing the initial development of the measures was to assign an Aggregate Diagnostic Service Category (ADSC) for the stay using the principal discharge diagnosis. To assign ADSC, download the ADSC Table (Table SPT-INP-ADSC) from the NCQA Web site (<http://www.ncqa.org/tabid/1092/Default.aspx>) and match the principal ICD-9-CM Diagnosis code from the discharge claim to an ADSC. If the claim does not contain a DRG and the primary ICD-9-CM Diagnosis code is invalid or missing, map the inpatient stay to the ADSC Table's MISA category. An alternative would be to create average prices from the dataset the measures are being implemented for each of the ADSC categories and discharge ICD-9-CM codes and assign those prices to missing hospitalizations.

Step 9 Determine if the member underwent major surgery during the inpatient stay. If this information is not available within the dataset, this may be determined using the list of codes included in a table from the NCQA Web site (Maj-Surg Table). Flag eligible members if one procedure code in the Maj-Surg-Table is present from any provider during the time period defined by the admission and discharge dates.

Step 10 Match each ADSC, LOS per diem multiplier, and major surgery flag assignment for the stay to a value in the Table SPT-INP-ADSC to obtain the assigned standard price. For each event, multiply the per-diem payment rate by the event's LOS per diem multiplier to determine the event's total standard cost. As with the DRG method, the ADSC standard prices must be adjusted for inflation to a reference period using the CPI. Between this ADSC methodology and the previously described DRG-based methodology, each inpatient hospital stay should now have an associated standardized price.

Example:

An eligible member had an inpatient stay with the following characteristics:

- A principal diagnosis for an eligible event assigned to ADSC category Respiratory-C (RESC)
- No available valid DRG information
- Date of admission of February 2, 2007 and date of discharge of February 9, 2007

- A LOS of 8 days, and therefore LOS group E
- A major surgery event during the stay

Using Sample Table SPT-INP-ADSC, we determine this event has a standard per-diem payment rate of \$1,474.00. Therefore this event has a calculated total standard cost of $\$1,474 \times 8 = \$11,792$.

Calculating Standard Units of Service and Total Standard Cost: Ambulatory Pharmacy

For ambulatory pharmacy-related costs, standardized prices are developed at the NDC level, adjusted for days supply.

Step 1 Identify all pharmacy services that occurred during the measurement period. The following pharmacy services should also be included:

- Prescriptions that may have been dispensed before the measurement period and had days supply that extended into the measurement period (e.g., a prescription with a dispensed date of December 15, 2007 and 30 days supply would extend 13 days into the measurement period beginning January 1, 2008)
- Prescriptions that may have been dispensed during the measurement period and had days supply that extended into the following period (e.g., a prescription with a dispensed date of December 20, 2008).

Define a single, unique record describing the pharmacy service.

Step 2 Identify the NDC code and the days supply for each prescription, whether or not some days fall outside the measurement period.

If the days supply is not available for a given pharmacy claim, set the claim's standard cost to be equal to its listed payment amount.

Step 3 Compute the days supply per diem multiplier. If the prescription's days supply fall completely within the measurement period, use the claim's listed days supply as the per diem multiplier. If the prescription's days supply do not fall completely inside the measurement period, count only the days within the measurement period (including the last day of the period) to compute the per diem multiplier.

Step 4 For each NDC, calculate the total NDC-specific payments and the total days supply across all pharmacy claims within that NDC during the measurement period. Using these totals, calculate NDC-specific per-day-supply payment rates by dividing total NDC-specific payments by total days supply for each NDC.

Step 5 Combine NDC-specific per-day-supply payment rates with the dataset containing eligible pharmacy events for the measure. For each event, multiply the per-day-supply payment rate by the event's days supply per diem multiplier to determine the event's total standard cost.

Calculating Standard Units of Service and Total Standard Cost: All Other

For all non-inpatient hospital, non-pharmacy costs, standardized prices are developed at the procedure code and modifier level.

Step 1 Identify all non-inpatient hospital, non-pharmacy services that occurred during the measurement period.

Step 2 Identify the primary procedure code (CPT, HCPCS, ICD-9, etc.) and the first modifier code for each service.

Step 3 For each procedure-modifier combination, calculate the total procedure/modifier-specific payments across all non-inpatient-hospital, non-pharmacy claims with that procedure-modifier combination as well as the frequency of the procedure-modifier combination during the measurement period. Calculate procedure/modifier-specific payment rates by dividing total procedure/modifier-specific payments by the frequency for each procedure-modifier combination.

Example:

Assume that there are 3 non-inpatient-hospital, non-pharmacy claims during the measurement period with the following characteristics:

Patient: 1111, Procedure (CPT-4): 71010, Modifier: Date: 2/1/2007, Payment: \$21

Patient: 1111, Procedure (CPT-4): 72240, Modifier: TC, Date: 2/18/2007, Payment: \$90

Patient: 2222, Procedure (CPT-4): 71010, Modifier: Date: 1/5/2007, Payment: \$25

For the procedure/modifier combination: 71010

The total payment is $\$21 + \$25 = \$46$

The total frequency is 2

Therefore the procedure/modifier-specific payment rate is $\$46/2 = \23

For the procedure/modifier combination: 72240/TC

The total payment is \$90
 The total frequency is 1
 Therefore the procedure/modifier-specific payment rate is $\$90/1 = \90

Step 4 Combine procedure/modifier-specific payment rates with the dataset containing eligible non-inpatient-hospital, non-pharmacy events for the measure so that each procedure-modifier combination is paired with its corresponding payment rate. This payment rate is the event's total standard cost.

Calculation of total individual episode costs

The resource use identified as diabetes-related– and to which standardized prices have been applied (i.e., the collection of eligible events) – is used to calculate individual level episode costs. The following steps are used in the calculation of total individual level costs.

Step 1: For each individual included in the episode, sum all of the total standard costs linked to diabetes-related events occurring during the measurement period at the BETOS service category level. This will provide an estimate of the costs of each category of service over the measurement period.

Step 2: For each individual in the episode, sum ALL total standard costs linked to diabetes-related events to calculate TOTAL episode costs.

Step 3: Exclude individuals that do not have positive, non-zero costs (e.g. outpatient visit, hospitalization, medication use) during the measurement period.

Rationale for costing method

We used standardized prices to estimate the costs for all components of care in the claims data that a patient received data during the measurement period. Because costs in claims data reflect both the quantity and mix of services delivered as well as the prices paid for those services, some of the cost variation is due to price differences across providers (Thomas et al., 2005). Variations in cost data among organizations and over time can obscure real cost differences (Ritzwoller, et al., 2004) and impede comparisons across providers. To ensure that comparisons are made on the basis of differences in practice patterns and resource use, we developed standardized prices, such that a given service would have the same price across all providers (Thomas et al., 2005). We used separate methods to estimate standardized price that were used to calculate for inpatient facility costs, pharmacy costs, and cost for all other care.

For the inpatient facility use, we developed standardized prices using diagnosis-related group (DRG) information. For hospitalizations without DRG-level information, we used aggregate diagnostic service category (ADSC) level information. In each case, we adjusted for length-of-stay (LOS) during the measurement period so as to more closely mirror the payment systems typically applied among commercial health plans. Both approaches use relative resource use (RRU) HEDIS standardized daily price tables developed by NCQA. We worked in collaboration with NCQA in development of this methodology; however, users of the measure may need to implement their own methodology that does not rely on a price list from NCQA.

For pharmacy use, we determined the days supply for each medication that was dispensed during the measurement period identified by a unique national drug code (NDC). We calculated a standardized price per diem for each NDC in our data by dividing the total payments in the claims data by the total days supply in the claims data for that NDC. We then estimated patient's pharmacy costs by multiplying the standardized price per diem for each NDC by the patient's days supply during the measurement period for that NDC. Standardized prices for pharmacy was estimated using this approach rather than an average whole price (AWP) because the AWP is not defined by law or regulation and does not reflect discounts obtained by most purchasers. As a result, the ultimate price paid by purchasers is often significantly lower than the AWP (Pereira, 2005).

For all other use, we identify the primary procedure code (CPT, HCPCs, ICD-9, etc.) and the first modifier code for each service. We calculated a standardized price for each procedure/modifier by dividing the total procedure/modifier-specific payments by the frequency for each procedure/modifier combination in the claims data. We then applied this standardized price to each patient's procedure/modifier combination that occurred during the measurement period. This approach allowed for a consistent methodology to be applied to each procedure/modifier combination in the claims data to achieve the same price for a service across all providers.

References:

Pereira BJJ. Medicare Prescription Drug, Improvement and Modernization Act: Average Wholesale Price (AWP)

Medscape Nephrology.2005;2(1)

Ritzwoller DP, Goodman MJ, Maciosek MV, Lafata JE, Meenan R, Hornbrook MC, Fishman PA. Creating Standard Cost Measures Across Integrated Health Care Delivery Systems. J Natl Cancer Inst Monogr 2005;35:80 – 87

Thomas JW, Grazier KL, Ward K. Economic Profiling of Primary Care Physicians: Consistency among Risk-Adjusted Measures. Health Services Research. 2004;39(4):985- 1004

S11. Measure Reporting (Resource Use Measure Module 5)

The measure developer must determine which of the following Measure Reporting functions: attribution approach, peer group, outliers and thresholds, sample size, and benchmarking and comparative estimates, are submitted as measure specifications or as guidelines. Specifications limit user options and flexibility and must be strictly adhered to; whereas guidelines are well thought out guidance to users while allowing for user flexibility. If the measure developer determines that the requested specification approach is better suited as guidelines, please select and submit guidelines, otherwise specifications must be provided.

S11.1. Detail attribution approach

Detail the attribution rule(s) used for attributing costs to providers and rationale for this methodology (e.g., a proportion of total measure cost or frequency of visits during the measure's measurement period) and provide rationale for this methodology.

Resource use and costs for chronic CHF episodes are attributed to one or more physicians on a hierarchical basis. The episode's total count of qualifying E&M codes by unique provider ID are used for provider attribution. For each episode identify all such E&M codes occurring during the measurement year. The E&M codes are used to assign attribution using the following hierarchy:

1. Costs and resource use are assigned to a single provider if that physician has at least 70% of the episode's E&M codes during the measurement year ("single attribution"); OR
2. If no provider has more than 70% of the E&M codes, costs and resource use are assigned to each of the providers that have at least 30% of the episode's E&M codes during the measurement year ("multiple attribution"); OR
3. If no provider has at least 30% of the episode's E&M codes during the measurement year, the costs and resource use for that patient are not attributed to any provider ("no attribution").

To identify the attributable provider, the following steps will be used:

Step 1: Identify qualifying E&M codes for the episode:

Evaluation and Management: CPT: Office or Other Outpatient Services 99201–99215; Hospital Observation Services 99217–99220; Hospital Inpatient Services 99221–99239; Consultations 99241–99275; Critical Care and Intensive Care Services 99289–99298; Nursing Facility, Domiciliary and Home Services 99301–99350; Case Management Services and Care Plan Oversight Services 99361–99380; Preventive Medicine Services 99381–99429; Other E&M Services 99450–99456, 99354–99357

Step 2: For every episode, count the total number of qualifying E&M codes and count the number of qualifying E&M codes for each unique provider id.

Step 3: For every episode and unique provider id combination, calculate the percentage of qualifying E&M codes using the formula below:

Percentage of Care = 100*(Episode's count of a provider's qualifying E&M codes divided by the Episode's total count of all qualifying E&M codes).

Step 4: Assign attribution based on the hierarchical attribution model described above.

Rationale:

A minimum of 30% of physician visits or physician costs has often been used as a minimum before an episode has been attributed to a physician (1,2). Similar to these previous efforts, our physician workgroup believed that this was a reasonable cutoff to define the minimum number of E&M codes before a physician received attribution. By the same token until a physician was responsible for 70% of E&M codes, it was believed by the physician workgroup that more than one physician shared responsibility for the costs of the episode and therefore multiple attribution was appropriate.

Further, an advantage of multiple attribution is that it increases the number of cases attributed to physicians – a factor that is important given the generally acknowledged problem of many physicians having too limited number of cases to allow them to be included in a comparison with other physicians. As to the use of E&M codes rather than payments to define attribution cutoff levels, the use of codes appears to be more transparent to physicians, especially given the use of standardized rather than actual payments and the fact that many expensive aspects of care resulting from physician decisions are not billed by that physician. Further, when primary physicians are involved in the episode, their physician-related payments are likely to be lower due to lower visit fees, yet it is more likely that they were responsible for referrals to specialists.

1. Merotra A, Adams JL, Thomas W, McGlynn A. The effect of different attribution rules on individual physician cost profiles. *Annals of Internal Medicine* 2010; 152:649-654.
2. Adams JL, Mehrotra A, Thomas JW, McGlynn EA. Physician cost profiling – reliability and risk of misclassification. *N England J Med*; 362: 1014-21.

S11.2. Identify and define peer group

Identify the peer group and detail how peer group is identified and provide rationale for this methodology

Guidelines : Peer group comparisons should be based on physician specialty (as user data sets allow) as providers should only be compared to those of the same specialty.

Focusing on comparing physicians of the same specialty is another mechanism to ensure the severity of patients is similar across providers. It is quite possible that patients predominantly seen by cardiologists or other specialists may be more complex or sicker patients than those seen by primary care physicians.

S11.3. Level of Analysis:

Clinician : Individual

S11.4. Detail measure outliers or thresholds

Detail any threshold or outlier rules and decisions based on measure resource use and provide rationale for this methodology

Guidelines : For the physician reports, total observed episode costs are winsorized at the 2nd and 98th percentile, but claim line outliers are not removed and the use of risk adjusted results are intended to correct for any extreme outliers. The only exception is inpatient admissions. Extremely high admissions costs are winsorized at the 99th percentile (i.e. any value higher than the 99th percentile are set to the 99th percentile cost).

Rationale: Winsorizing and risk adjustment limits the influence of outliers. Episodes with extremely high admission costs skews mean costs for the entire episode. Winsorizing admissions at the 99th percentile reduces this effect without eliminating information on the distribution of total episode costs.

S11.5. Detail sample size requirements

Detail the sample size requirement including rules associated with the type of measure

We do not provide specifications or guidelines for sample size requirements : The ABMS REF episode-based resource use measures do not randomly sample enrollees nor do we recommend that implementers construct measures from a random sample. Regarding the issue of sample size determination. It is well known that the nature of resource use measurement at the level of individual providers will often lead to unstable estimations. There have been a number of efforts to derive a single number for which such measures might be stable enough for comparison of providers or individual providers over time. Yet to date there is no commonly accepted minimum. At this time we have not attempted to derive a minimal sample size for measure use.

S11.6. Define benchmarking or comparative estimates

Detail steps to produce benchmarking and comparative estimates and provide rationale for this methodology

Guidelines : Creation of provider summaries

The provider summaries are a report of the resource use for an attributable unit (hospital or provider) compared to their

peer group, their non-peer group and all episodes in the dataset. Creation of the provider summaries uses the summary episode costs combined with the attributable provider data and the risk adjusted episode costs.

Step 1: Create a dataset that includes the following information: patient ID, total episode cost, attributable provider ID (or ID for the attributable unit if at the hospital level), attributable provider specialty type and episode expected costs from the risk adjustment model.

Step 2: Calculate the observed-to-expected ratio for each of the episodes by dividing observed costs for the episode by expected (predicted) costs for the episode.

$$\text{O-to-E} = \text{Sum of Observed Costs} / \text{Expected Costs from Risk Adjustment Model}$$

Step 3: If applicable, create indicators for the strata the episodes fall into so that separate summaries can be created for each of the strata.

Step 4: Summarize the observed, expected and observed-to-expected ratio for each attributable provider. Report minimum, maximum, median and mean values of the observed-to-expected ratio for all episodes attributed to the provider.

Step 5: Summarize the observed, expected and observed-to-expected ratio for each provider type, overall, and within each strata (if applicable). Report summary statistics for each of the provider types so the data are summarized for all providers of the same type. For example, report the summary statistics for the observed-to-expected ratio for all of the family practice physicians to facilitate peer group comparisons.

Step 6: Summarize the observed, expected, and observed-to-expected ratio for all of the episodes.

Step 7: For each of the individual attributable units (hospital or provider), determine the proportion of O-to-E ratios that are greater than or equal to the 75th percentile of the O-to-E ratio for the peer group. Calculate the 95% confidence interval for the proportion. For example, if the provider for which summary statistics are being calculated is a general internist and it is Dr. Y, the 75th percentile of O-to-E ratios for all episodes attributable to general interests is determined. The proportion of Dr. Y's O-to-E ratio that are above the 75th percentile for all general interest episodes is determined and a 95% confidence interval is calculated for that proportion.

Step 8: Create provider summary reports for each attributable provider in the dataset

S12.Type of Score:

Ratio

If available, please provide a sample report:

[S12_sample score report.pdf](#)

S12.1. Interpretation of Score.

(Classifies interpretation of score (s) according to whether higher or lower resource use amounts is associated with a higher or lower score, a score falling within a defined interval, or a passing score, etc)

The summary score calculated for the measure is the ratio of the observed cost to the expected cost or the O-to-E ratio. The O-to-E ratio is calculated for each patient for the attributable provider and summary statistics are calculated for the O-to-E ratio. The O-to-E ratio provides an estimate of the observed cost for a patient to the expected cost based on the patient's mix of chronic conditions. Expected costs for each patient are the calculation of their risk adjusted costs. A value of 1 for the O-to-E ratio indicates that the observed costs are equal to the expected costs. A value greater than 1 indicates that observed costs are more than what would be expected based on the patient's mix of chronic conditions. A value less than 1 indicates that the observed costs are less than what would be expected based on the patient's mix of chronic conditions. Calculation of the O-to-E ratio incorporates our approach to risk adjustment by determining the expected costs from the risk adjustment model. A summary O-to-E ratio is calculated for each of the attributable providers which combines all the episodes for that provider. Summary statistics are calculated for each provider for the raw (unadjusted) costs for the episode, expected costs and the O-to-E ratio. Each summary measure includes minimum, maximum, median, and mean values.

S12.2. Detail Score Estimation

Detail steps to estimate measure score.**Creation of provider summaries**

The provider summaries are a report of the resource use for an attributable unit (hospital or provider) compared to their peer group, their non-peer group and all episodes in the dataset. Creation of the provider summaries uses the summary episode costs combined with the attributable provider data and the risk adjusted episode costs.

Step 1: Create a dataset that includes the following information: patient ID, total episode cost, attributable provider ID (or ID for the attributable unit if at the hospital level), attributable provider specialty type and episode expected costs from the risk adjustment model.

Step 2: Calculate the observed-to-expected ratio for each of the episodes by dividing observed costs for the episode by expected (predicted) costs for the episode.

$$\text{O-to-E} = \text{Sum of Observed Costs} / \text{Expected Costs from Risk Adjustment Model}$$

Step 3: If applicable, create indicators for the strata the episodes fall into so that separate summaries can be created for each of the strata.

Step 4: Summarize the observed, expected and observed-to-expected ratio for each attributable provider. Report minimum, maximum, median and mean values of the observed-to-expected ratio for all episodes attributed to the provider.

Step 5: Summarize the observed, expected and observed-to-expected ratio for each provider type, overall, and within each strata (if applicable). Report summary statistics for each of the provider types so the data are summarized for all providers of the same type. For example, report the summary statistics for the observed-to-expected ratio for all of the family practice physicians to facilitate peer group comparisons.

Step 6: Summarize the observed, expected, and observed-to-expected ratio for all of the episodes.

Step 7: For each of the individual attributable units (hospital or provider), determine the proportion of O-to-E ratios that are greater than or equal to the 75th percentile of the O-to-E ratio for the peer group. Calculate the 95% confidence interval for the proportion. For example, if the provider for which summary statistics are being calculated is a general internist and it is Dr. Y, the 75th percentile of O-to-E ratios for all episodes attributable to general interests is determined. The proportion of Dr. Y's O-to-E ratio that are above the 75th percentile for all general interest episodes is determined and a 95% confidence interval is calculated for that proportion.

Step 8: Create provider summary reports for each attributable provider in the dataset

S12.3. Describe discriminating results approach***Detail methods for discriminating differences (reporting with descriptive statistics--e.g., distribution, confidence intervals)***

Summary reports are generated at the attribution level that includes a summary estimate for the provider or hospital, the peer group, the non-peer group and the overall summary for the episode in the entire population. For each attributable provider / hospital the observed, expected and O-to-E ratio are summarized. The summaries are created to facilitate comparisons for the attributable provider or hospital with other providers in the same peer group and overall. The most meaningful comparisons are likely those between the provider or hospital and the peer group. Even though the results are risk adjusted, this may help to further balance the case mix or severity of the patients being compared. The summary statistics for the O-to-E ratios can be compared in order to provide a sense of the relative performance of the provider or hospital compared to peers. In addition, the proportion of O-to-E ratios about thresholds of 2.0 and 2.5 are provided for comparisons. Finally, for the attributable unit (hospital or provider) the proportion of O-to-E ratios that are greater than or equal to the 75th percentile of the O-to-E ratio for the peer group is determined and the 95% confidence interval calculated. The expectation would be that 25% of the estimates for the attributable provider would fall about this value if the distribution of O-to-E ratios is similar to the peer group. A statistically significant difference would be found between the groups if the 95% confidence interval did not include 25% in the range. For example, if the proportion at or above the 75th percentile of the peer group is 38% and the 95% confidence interval ranges from 28% to 48% then this provider would have significantly more O-to-E ratios at the upper end of the distribution than the peer providers. Alternatively, if the proportion at or above the 75th percentile was 8% and the 95% confidence interval ranged from 3% to 16% then the provider would have significantly fewer O-to-E ratios in the upper end of the distribution than the peer group. The 75th percentile in our testing was selected as an illustrative cut-point and it will be important to evaluate this threshold for comparing providers.

TESTING/ANALYSIS	
<p>Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. See guidance on measure testing.</p>	Eval Rating
<p>TESTING ATTACHMENT (5MB or less) or URL: <i>If needed, attach <u>supplemental</u> documentation (Save file as: SA_Reliability_Validity Testing) All fields of the submission form that are supplemented within the attachment must include a summary of important information included in the attachment and its intended purpose, including any references to page numbers, tables, text, etc.</i></p> <p style="margin-left: 20px;">URL: Please supply the username and password: Attachment: SA_Reliability_Validity Testing CHF Chronic.pdf</p>	
<p>SA1. Reliability Testing <i>For each module tested or for the overall measure score:</i></p> <p>SA1.1. Data/sample <i>(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)</i></p> <p>Thomson Reuter’s MarketScan Dataset was used in the testing of the ABMS REF episode-based resource use measures.</p> <p>The MarketScan Commercial Database provides a rich, comprehensive source of longitudinal administrative claims data, offering the largest convenience sample available in proprietary databases with over 30 million covered lives in each of the three most current years of data. The MarketScan Commercial Claims and Encounters (Commercial) Database is constructed from data contributed from over 100 medium and large size employers and health plans, representing over 130 unique carriers. The MarketScan Databases’ large sample size constitutes a nationally representative data sample of the U.S. population under the age of 65 with employer-sponsored health insurance.</p> <p>The stability of MarketScan data sources provides superior continuity of patients over multiple years, generally longer than other claims databases because the majority of the MarketScan data are sourced from large employers. As long as individuals remain with the same employer, they can be tracked across health plans.</p> <p>Features of the MarketScan Research Databases include:</p> <ul style="list-style-type: none"> • Fully paid and adjudicated claims including inpatient, outpatient, and prescription drug claims • Complete payment/charge information, including amount of patient responsibility • Validated diagnosis, procedure, and other standard codes on claims where applicable (CPT, ICD-9, DRG, NDC, etc) • Demographic information on enrollees including age, gender, and geographic information (three-digit zip codes and MSA) • Plan-type identifiers in the database include major medical, comprehensive, PPO, EPO, HMO, consumer-driven health plan, capitated or part-capitated POS and non capitated POS • Standardized data elements and definitions, ensuring accurate comparisons • Clinical data enhancements, such as Therapeutic Class and Generic Product Identifiers on drug records, and Major Diagnostic Categories and Diagnosis Related Groups on inpatient and outpatient records • Case records linking all of the hospital, physician, and ancillary services provided during an inpatient stay, allowing for comparisons based on such statistics as average length of stay, cost per admission, etc. <p>These data reflect the real world of treatment patterns and costs by tracking millions of patients as they travel through the healthcare system, offering detailed information about all aspects of care. Data from individual patients are integrated from all providers of care, maintaining all healthcare utilization and cost record connections at the patient level.</p>	2a2

H
M
L
I

SA1.2. Analytic Methods
(Describe method of reliability testing and rationale)

Reliability refers to the reproducibility of results (Bannigan and Watson, 2009). To investigate the reliability of the measure, we examined the means, medians and distribution of costs across categories of care (inpatient facility charge, evaluation and management, procedures, etc.) for all individuals with CHF in the MarketScan data who met inclusion/exclusion criteria and for a subsample of this cohort. After applying inclusion criteria to the MarketScan data, we identified 38,441 episodes of CHF (see attached data summary Slide 4). After applying the exclusion criteria, there were 11,494 episodes of CHF for the measure. The subsample of this cohort was obtained as part of our investigation of the attribution of episodes of care to providers. To examine the attribution of episodes of care to providers, we first had to determine which providers had provider identification codes in the MarketScan data. There were 46.3% of episodes for which we were able to assign attribution. Then, we examined the distribution of costs across categories of care for the entire cohort and the subsample. Rationale: Our investigation of reliability allowed us to leverage on analyses that were being done to examine overall resource use and attribution of care.

Reference: Bannigan K, Watson R. Reliability and validity in a nutshell *Journal of Clinical Nursing*. 2009;18: 3237–3243

SA1.3. Testing Results
(reliability statistics, assessment of adequacy in the context of norms for the test conducted)

For all episodes of CHF in the MarketScan data that met the inclusion/exclusion criteria (i.e., 11,494 episodes), inpatient facility charges and drugs comprised the largest portion of costs (see attached data summary Slide 6). Moreover, inpatient facility charges were most relevant for episodes whose costs were in the highest 95th percentile of costs. Among the subsample of episodes for which a provider could be attributed, inpatient facility charges and drugs also comprised the largest portion of costs with inpatient facility charges being most relevant in for episodes in the highest 95th percentile of costs (see attached data summary Slide 23).

SA1.4. Finding statement(s)—*(i.e., is the measure deemed reliable, limitations identified)*

The results of our comparison would suggest that the measure could be deemed reliable. It should be noted that this investigation highlighted a limitation of the data regarding the portion of missing provider identifiers.

SA2. Validity Testing
For each module tested or for the overall measure score:

SA2.1. Data/Sample
(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)

See section SA1.1 for description of Thomson Reuters MarketScan dataset.

SA2.2. Analytic Method
(Describe method of validity testing and rationale; if face validity, describe systematic assessment)

Validity testing focused primarily on face validity. Initial testing included:

Level 1 analyses

- o Examined impact of inclusion/exclusion criteria on episode denominator
- o Examined total episode spending by type of service--means, medians and distributions
- o Identified top 20 “condition-related” and “non-condition-related” E&M, procedures, imaging, tests, inpatient admissions (by ICD-9 and DRG) and drugs, by service counts and dollar volume
- o Tested proposed attribution logic, examined variability in per-episode resource use at individual provider level (as relevant) and by provider specialty.

Level 2 analyses

- o Incorporated risk adjustment
- o Produced sample physician-level reports in which observed-to-expected ratios are computed and the

2b2

H
M
L
I

distribution of each physician’s episodes is compared to the peer group’s distribution.

- o Examined specific drivers of resource use variation
- o Examined variability in per-episode resource use across regions, states and the specialties of attributed providers.

Throughout the process of empirically testing the measures, summary analyses were presented to the workgroups for review and discussion. The workgroups reviewed denominator attrition diagrams to assess how the measure’s inclusion and exclusion criteria affected the episode’s denominator. They also reviewed summaries of costs by type of service (inpatient hospital care, outpatient care, procedures, imaging, tests, and prescription drugs) and were asked to assess whether the distributions matched the clinical expectations for the condition’s treatment. The clinicians were also presented with analyses of diagnosis and procedure level details in order to ensure that appropriate services were being captured and grouped to the episodes. At each step in the process, the measure specifications were revised based on workgroup feedback.

In addition to workgroup feedback results of the preliminary testing were also shared with a Technical Advisory Committee and the QASC Episodes Work Group and the measures revised according to feedback.

By presenting our results to the clinical workgroups and others to examine the distributions of resource use and costs to determine if these results meant their clinical expectations, we were able to access the face validity of our results.

SA2.3. Testing Results

(statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment)

We have developed a measure specification to measure resource use associated with an episode of care for chronic management of CHF. The measure includes resource use related to chronic management of CHF over a 1-year period in order to capture all CHF-related annual costs of treating these patients. For the Level 1 analysis, we found that there were 38,441 individuals meeting our inclusion criteria and 11,494 individuals after applying our exclusion criteria (see attached data summary Slide 4). We found that the average total cost of a CHF episode was \$3,511, and the predominating costs of the episode were drug charges (40% of the total costs) and inpatient facility charges (17%). The next highest cost categories were for imaging (13%) and evaluation and management (10%). We were able to attribute 46.3% of the episodes to providers in our data due (53.6% could not be attributed due to missing provider identifiers) (see attached data summary Slide 21). We found that 77.4% of episodes could be attributed to a single provider and 21.8% of episodes could be attributed to multiple providers. As part of the Level 2 analyses, we examined variability in per episode resource use by specialties of the attributed providers. The highest volume specialty was cardiology (see attached data summary Slide 26). It would be expected that drugs and inpatient facility charges would be a large component of costs for patients with CHF because management of cardiovascular disease involves proper therapeutic selection from the pharmacologic, interventional, and mechanical options available (Almeda & Hollenberg, 2003). It would also be expected that cardiology would account for a high volume of resource use. These results were presented to the clinical workgroup who concurred that these results met their clinical expectations and had face validity.

Reference: Almeda FQ, Hollenberg SM. Update on therapy for acute and chronic heart failure. Applying advances in outpatient management. Postgrad Med. 2003 Mar;113(3):36-8, 41-4, 47-8

SA2.4. Finding statement(s)—(i.e., is the measure deemed reliable, limitations identified)

Based on the results of our investigations and concurrence from the clinical workgroup, our measure should be deemed to have face validity.

SA3. Testing for Measure Exclusions

2b3

SA3.1. Describe how the impact of exclusions (if specified) is transparent as required in the criteria

In the attached data summary, we have detailed how the exclusions impacted the resulting size of the cohort (see attached data summary Slide 4).

SA3.2. Data/sample for analysis of exclusions

(Description of the data or sample including number of measured entities; number of patients; dates

<p><i>of data; if a sample, characteristics of the entities included)</i></p> <p>See section SA1.1 for description of Thomson Reuters Marketscan dataset.</p> <p>SA3.3. Analytic Method <i>(Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference)</i></p> <p>We examined the impact of several types of exclusions. In order to ensure that data are available for assessing the episode of care, we excluded individuals without continuous insurance coverage including medical and pharmacy benefits. We also excluded individuals who met standard NCQA exclusions for conditions that are resource intensive, which could potentially have a larger impact on resource use than the condition being studied (i.e., end stage renal disease, active cancer management, etc.) There were also exclusion criteria that were specified for this condition by the clinical workgroup: age < 18 years, hospitalization for CHF in prior 6 months and presence of mechanical assist devices. We examined the impact of these exclusions on the resulting cohort size.</p> <p>SA3.4. Results <i>(Statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses)</i></p> <p>The exclusion of individuals without continuous enrollment in health insurance with medical and pharmacy benefits had the largest impact on the cohort size. Among the 38,441 individuals who met the inclusion criteria for the measure, 15,302 (or 39.8% of the total) remained after the continuous enrollment exclusion criteria were applied (see attached data summary Slide 4). Among the other exclusion criteria, 8% of individuals met the NCQA exclusion criteria, 14.1% were hospitalized during the prior 6 months, 4% had mechanical assist devices, and 0.7% were < 18 years of age.</p> <p>SA3.5. Finding statement(s)-- <i>(i.e., is the measure deemed reliable, limitations identified)</i></p> <p>Based on the results of our analyses and feedback from the clinical workgroup, we would deem the measure to be reliable. Our investigation did find that a substantial portion of individuals were excluded due to the continuous enrollment criteria, which is related to the data itself rather than the clinical characteristics of the individuals.</p> <p>SA4. Testing Population <i>Which populations were included in the testing data? (Check all that apply)</i></p> <p>Commercial</p>	<p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p>
<p>SA5. Risk adjustment strategy</p> <p><i>Refer to items S10.1 and S10.2 to rate this criterion.</i></p>	<p>2b4</p> <p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p>
<p>SA6. Data analysis and scoring methods</p> <p><i>Refer to items S12-S12.3 to rate this criterion.</i></p>	<p>2b5</p> <p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p>
<p>SA7. Multiple data sources</p> <p><i>Refer to S7 & all SA1 items to evaluate this criterion.</i></p>	<p>2b6</p> <p>H <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>L <input type="checkbox"/></p> <p>I <input type="checkbox"/></p> <p>NA <input type="checkbox"/></p>
<p>SA6. Stratification of Disparities (if applicable)</p>	<p>2c</p>

<p>Refer to item S10.2 to rate this criterion.</p>	<p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Scientific Acceptability of Measure Properties</i>?</p>	
<p>Steering Committee: Overall, was the criterion, <i>Scientific Acceptability of Measure Properties</i>, met? Rationale:</p>	<p>Y <input type="checkbox"/> N <input type="checkbox"/></p>
<p>USABILITY</p>	
<p>Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making.</p>	<p>Eval Rating</p>
<p>Meaningful, Understandable, and Useful Information</p> <p>U1. Current Use:</p> <p>Public reporting (disclosure to performance results to the public at large) Quality improvement with external benchmarking</p> <p>U1.1. Use in Public Reporting Initiative Use in Public Reporting. <i>Disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s). If not publicly reported in a national or community program, state the plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement)</i></p> <p>The ABMS REF has only recently completed the development and testing of its Episode-based Resource Use Measures. The Robert Wood Johnson Foundation has provided follow-up funding in the form of technical assistance to Aligning Forces for Quality (AF4Q) communities for continued testing of the measures—a 15-month award to Brookings Institute with a subcontract to ABMS REF for continued field testing of select measures in up to four AF4Q communities toward the goal of public reporting and quality improvement benchmarking.</p> <p>U1.2. Use in QI <i>(If used in improvement programs, provide name of program(s), locations, Web page URL(s)).</i></p> <p>See Section U1.1 above.</p> <p>U1.3. Use for other Accountability Functions (payment, certification, accreditation) <i>(If used in a public accountability program, provide name of program(s), locations, Web page URL(s)).</i></p> <p>See section U1.1 above.</p>	<p style="text-align: center;">3a</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>U2. Testing of Interpretability <i>(Provide a rationale for why the measure performance results are meaningful, understandable, and useful to the intended audience(s) for both public reporting and quality improvement).</i></p> <p>U2.1. If understanding or usefulness was demonstrated <i>(e.g., through systematic feedback from users, focus group, cognitive testing, analysis of quality improvement initiatives) describe the data, methods, and results.</i></p> <p>The ABMS REF measures have not yet been tested for usefulness or interpretability. They are currently undergoing continued testing in up to four AF4Q communities.</p>	<p style="text-align: center;">3b</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> NA <input type="checkbox"/></p>

<p>U2.2. Resource use data and result can be decomposed for transparency and understanding. <i>Refer to items S11 -S12.3.</i></p>	<p>3c H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>U3. If there are similar or related measures (either same measure focus or target population) measures (both the same measure focus and same target population), list the NQF # and title of all related and/or similar measures.</p> <p>U3.1. If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s): Are the measure specifications completely harmonized?</p> <p>U3.2. If the measure specifications are not completely harmonized identify the differences, rationale, and impact on interpretability and data collection burden. <i>Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible.)</i></p>	<p>3d H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/> NA <input type="checkbox"/></p>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Usability</i>?</p>	
<p>Steering Committee: Overall, to what extent was the criterion, <i>Usability</i>, met? Rationale:</p>	<p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/></p>
<p style="text-align: center;">FEASIBILITY</p>	
<p>Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement.</p>	<p>Eval Rating</p>
<p>F1. Data Elements Generated as Byproduct of Care Processes <i>How are the data elements needed to compute measure scores generated? Data used in the measure are:</i></p> <p>Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)</p>	<p>4a H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>F2. Electronic Sources <i>Are the data elements needed for the measure as specified available electronically? (Elements that are needed to compute measure scores are in defined, computer-readable fields)</i></p> <p>ALL data elements in electronic claims</p> <p>F2.1. If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources.</p>	<p>4b H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>

<p>F3. Susceptibility to Inaccuracies, Errors, or Unintended Consequences <i>Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to minimize or prevent. If audited, provide results.</i></p> <p>The majority of measures developed for this project are of 12 months duration or less with identification of the population in one year and measurement in the following. This resulted in eligibility criteria requiring a minimum of 24 months of continuous data (full medical and pharmacy benefit enrollment). Often, clinical workgroup members expressed a desire to extend the duration of a measure to encompass more longitudinal clinical outcomes (e.g. cardiac complications for diabetes) however this was not practical due to the typical enrollment patterns in the commercial population.</p> <ul style="list-style-type: none"> • Sample size may be of concern for implementers seeking to measure resource use at the level of the individual provider. Many of the measures, when tested on commercial datasets, resulted in small sample sizes that may prohibit meaningful attribution. Discontinuous medical coverage and missing pharmacy coverage were responsible for significant (often greater than 50%) decreases in eligible populations, emphasizing the trade-offs between ensuring adequate sample size and achieving specificity/homogeneity in the measure denominator. If users are unable to achieve adequate sample size at the level of the individual provider, the measures specifications may still provide valuable information at the level of group, system or region. • Administrative claims lack the detail necessary to fully understand appropriateness of resource use in relation to severity of disease (e.g. bundled hospital payments, absence of cancer staging information, absence of cardiac severity indicators, Type 1 v. Type 2 diabetes). Future efforts should consider the integration of administrative claims with other sources of clinical information such as registries and electronic health records. • Resource use is only one component of efficiency measurement. The measures created in this project are not intended to be used in isolation to evaluate physician performance; rather they are intended to complement quality measures as an important component of performance evaluation. • The measures developed in this project represent a small subset of clinical conditions, and do not address the full range of patient and provider experience. Each measure was developed independently and, as such, they are not summative. Efforts to sum multiple measures will result in double counting of services. • The standardized pricing algorithms used for testing the measures were developed for use in the Marketscan dataset. The technical appendices accompanying the measures provide a guide to assist users in developing their own set of standardized prices unique to their datasets. Until a national list of standardized prices is made available to the general public, the methods employed in the testing phase of this project do not allow for national benchmarking. 	<p>4c</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>F4. Data Collection Strategy <i>Describe what you have learned/modified as a result of testing regarding barriers to operational use of the measure (e.g., availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, cost of proprietary measures).</i></p> <p>Administrative claims lack the detail necessary to fully understand appropriateness of resource use in relation to severity of disease (e.g. bundled hospital payments, absence of cancer staging information, absence of cardiac severity indicators, Type 1 v. Type 2 diabetes). Future efforts should consider the integration of administrative claims with other sources of clinical information such as registries and electronic health records.</p> <p>There were several lessons learned throughout the development and testing of the ABMS REF episode-based resource use measures. First, was the importance of garnering a diverse range of clinical input in a transparent manner to foster face validity and acceptance in the clinical community. Second was the importance of adequate resources for data acquisition, preparation and analyses (time and personnel). Not all datasets are formatted the same which can lead to significant amounts of programmer time for re-formatting code or datasets. It is also important to allow 2-6 months lead time to negotiate data use agreements as use of health care data—even de-identified data—often involves complex contract negotiations.</p>	<p>4d</p> <p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/> I <input type="checkbox"/></p>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Feasibility</i>?</p>	
<p>Steering Committee: Overall, to what extent was the criterion, <i>Feasibility</i>, met? Rationale:</p>	<p>H <input type="checkbox"/> M <input type="checkbox"/> L <input type="checkbox"/></p>

RECOMMENDATION

Steering Committee: Do you recommend for endorsement?
 Comments:

Y
 N
 A

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner)

Co.1 Organization

American Board of Medical Specialties Research and Education Foundation, 222 N. LaSalle St., Suite 1500, Chicago, Illinois, 60601

Co.2 Point of Contact

Kevin, Weiaa, MD, kweiss@abms.org, 312-436-2600-

Measure Developer If different from Measure Steward

Co.3 Organization

American Board of Medical Specialties Research and Education Foundation, 222 N. LaSalle St., Suite 1500, Chicago, Illinois, 60601

Co.4 Point of Contact

Kevin, Weiaa, MD, kweiss@abms.org, 312-436-2600-

Co.5 Submitter If different from Measure Steward POC

Robin, Wagner, rwagner@abms.org, 312-436-2605-, American Board of Medical Specialties research and Education Foundation

Co.6 Additional organizations that sponsored/participated in measure development

Development of the ABMS REF Episode-based Resource Use Measures was supported by the Robert Wood Johnson Foundation under the High Value Healthcare Project: Characterizing Episodes and Costs of Care. Grant number 63609.

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.

Congestive Heart Failure Workgroup Members
 William Dalsey, MD, American College of Emergency Physicians
 Mihai Gheorghiade, MD, American College of Cardiology
 Peter Hollmann, MD, American Geriatrics Society
 Joanna Sikkema, MSN ANP-BC, American Nurses Association
 Ted Ganiats, MD, American Academy of Family Physicians
 Workgroups consisting of a panel of experts were assembled for each condition. In collaboration with the AMA PCPI, a formal call for nominations was issued to the PCPI membership. This process was supplemented with direct outreach to relevant organizations in an effort to achieve representation from a wide range of clinical expertise (medical, nursing, pharmacy, other allied health professionals). Workgroup members were selected based on their clinical knowledge and administrative experience—many also had significant experience in developing quality measures. Where possible, groups also included

technical expertise from the health plan perspective.

The measure development process involved a series of deliberate steps where participating clinicians took into account the natural progression of a condition and existing best practices before carefully considering how to best use administrative claims data to construct the episode.

Each clinical workgroup initially convened for a two-day in-person meeting that began with an introduction to the concepts of episodes of care and resource use measurement-- including a review of the NQF framework for evaluating efficiency across episodes of care. The groups were then asked to conceptualize one or more episodes based on the phases of the NQF model. They aimed to identify clinically homogenous populations so that the measures would be sensitive to provider decisions and existing practice protocols for like patients. Workgroup members were then asked to conceptualize the measure specifications based on their combined knowledge of guidelines, evidence, and clinical experience. The workgroups helped to define the denominator, duration, clinically relevant services and attribution of each episode as related to the clinical progression and treatment of the condition.

Throughout the months following the in-person meeting, project staff then worked to translate the concepts into detailed written measure specifications. The workgroups subsequently re-convened via a series of conference calls to review data analyses, share expert opinions, consider additional evidence-based literature, revise and finalize the measure specifications.

Measure Developer/Steward Updates and Ongoing Maintenance

Ad.2 Year the measure was first released:

2010

Ad.3 Month and Year of most recent revision:

12, 2010

Ad.4 What is your frequency for review/update of this measure?

every 3 years

Ad.5 When is the next scheduled review/update for this measure?

12, 2013

Ad.6 Copyright statement/disclaimers:

The Episode-based Resource Use Measures (Measures) and related data specifications, developed by the American Board of Medical Specialties Research and Education Foundation (ABMS REF), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These Measures are not clinical guidelines and do not establish a standard of medical care. The ABMS REF has not tested its Measures for all potential applications. The ABMS REF encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the ABMS REF. The Measures may not be altered without the prior written approval of the ABMS REF. The Measures developed by the ABMS REF, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and ABMS REF. Neither the ABMS REF nor its members shall be responsible for any use of these Measures.

Portions of the exclusion criteria in the ABMS REF episode-based resource use measures were adapted from HEDIS ® measure specifications.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The ABMS REF disclaims all liability for use or accuracy of coding contained in the specifications.

Current Procedural Terminology (CPT ®) contained in the Measures specifications is copyright 2004 -2010 American Medical Association. All rights reserved.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Copyright 2011 American Board of Medical Specialties Research and Education Foundation. All Rights Reserved.


Ad. 7 Date of Submission (MM/DD/YY):

03/18/2011

Comparison ‘off the shelf’ HCC Values with Episode-specific Risk Adjustment Model

Below we show the figure for the comparison of the diabetes risk adjustment model with diabetes risk adjustment models if we had used HCC values. The first box plot in the figure shows the observed costs in for the episode. The second box plot shows the risk adjustment model that we developed for our diabetes episode that is focused on diabetes-related costs. The final five box plots show the distribution of predicted costs including different HCCs for our diabetes episode if we had relied on the off the shelf HCC values. The mean predicted value for all of the off the shelf HCCs models is \$1500 or less, while the observed episode costs were slightly more than \$4,000. Given the disparity in the means and distributions of the off the shelf HCC values we felt this justified our approach to develop risk adjustment models for each of our episodes that were focused on episode specific costs

Observed and Predicted Values – Diabetes Episode with “off the shelf HCCs”



12

For this reason, we have developed separate risk adjustment models for each of our episodes that are based on episode-specific costs. We realize this increases the complexity of implementing our measures; however, we feel it is a more appropriate approach for risk adjustment within our episodes. Within our risk adjustment approach, we control for different comorbidities for each condition because patients with each of the measurement conditions often had very different risk profiles.

We used the following risk adjustment strategy in the development of our risk adjustment models:

1. Utilized quasi-Modified Delphi approach with the condition-specific workgroup to categorize HCCs into three groups:

- Include in risk adjustment model;
- Exclude in risk adjustment model; and
- Test impact in risk adjustment model.

2. Identified HCCs in denominator population during the 12 months before the measurement year.

3. Tested 12 different model specifications shown in Table 1 (below), where the HCCs included in the model varied, and the distribution and link functions in the generalized linear models also varied. Models were developed in a stepwise manner as indicated. The first four models used a gamma distribution and a log link function. This functional form of the model was selected as cost data are typically skewed and we wanted to account for that in the analysis. The first model included all HCCs identified by the condition-specific workgroup as “Include HCCs” with a prevalence in the population of $\geq 1\%$. The second model was a reduction of the first model that only included HCCs where $p < 0.1$. The third model extended the second model by including HCCs with prevalence $\geq 1\%$ identified as “Test HCCs” by the condition-specific workgroup. The fourth model was a reduction of the third model and included only those HCCs where $p < 0.1$. The next set of four models (Models 5-8) repeated the process of the first four models but used a normal distribution and identity link function. We opted to include this functional form of the model so that the model output could be interpreted in dollars without requiring a transformation. We followed this strategy as we felt it would be easier for those implementing our measure to create their own risk adjustment models using this functional form of the model if they decided to create their own models. Finally, we opted to evaluate models that included all of the HCCs in case the work group may have failed to include HCCs that were influential on the overall episode costs. Model 9 used all of the HCCs, with the exception of the HCC for the episode being evaluated (e.g., diabetes for the diabetes episode; however HCCs for complications of diabetes were included), and a gamma distribution with log link function. Model 10 was a reduction of Model 9 where only the HCCs with $p < 0.1$ were included. The final two models (Models 11-12) used the same process as Models 9 and 10 with a normal distribution and identity link function.

Table 1. Risk Adjustment Model Specifications

Model #	Independent Variables						Distri- bution	Link function
	WG Specified (> 1%)	WG specified (> 1%) p < 0.1	Test condition s (> 1%)	Test condition s (> 1%) p < 0.1	All HCCs	All HCCs p < 0.1		
1	X						Gamma	Log
2		X					Gamma	Log
3		X	X				Gamma	Log
4		X		X			Gamma	Log
5	X						Normal	Identity
6		X					Normal	Identity
7		X	X				Normal	Identity
8		X		X			Normal	Identity
9					X		Gamma	Log
10						X	Gamma	Log
11					X		Normal	Identity
12						X	Normal	Identity

4. Models were developed in a split sample approach with 75% of the population randomly selected for model development and the remaining 25% used in model evaluation. Model performance was also evaluated in the full cohort.

5. The performance of each model was evaluated through comparisons of the observed and predicted distributions, comparisons of residuals, comparisons of absolute differences between observed and predicted, comparisons of observed-to-predicted ratios, and comparisons of mean squared errors across models. Summary information on model performance was presented to the condition-specific workgroup for selection of a risk adjustment model for the condition. Final model selection was based on the best performing model across metrics. Where model performance was similar, models using the normal distribution were preferentially chosen over the gamma distribution models for ease of implementation. More parsimonious models were also preferentially chosen.

High-Value Health Care Project - Characterizing Episodes and Costs of Care (C3)
Data Elements Required to Calculate C3 Measures

Variable Name	Variable Description	Required Data Sources*
admdate	Date of Admission	A
age	Age	E
billtyp	Facility Bill Type Code	C
days	Length of Stay	A
daysupp	Day's Supply	D
disdate	Date of Discharge	A
drg	Diagnosis related group	A,B
dstatus	Discharge status	A
egeoloc	Geographic Location	E
enrolid	Enrollee ID	All
fachdid	Facility Header Record ID	C
facprof	Professional/Facility Indicator	C
genme	Generic Drug Name	D
mastfrm	Master Form Code	D
memdays	Member Days	E
ndcnum	National Drug Code (ndc_code in Redbook)	D
pay	Payment	A,B,C,D
pdx,dx1,dx2,...,dxn	Diagnosis Codes	A,B,C
physid	Physician ID	A,B
pproc, pproc1,..., pprocn	Procedure/Service Codes	A,B,C
procmod	Procedure Code Modifier	A,C
proctyp	Procedure Code Type	B,C
prodnme	Product Name	D
provid	Provider ID	A
qty	Quantity of Services	A,B,C,D
region	Region	E
revcode	Revenue Code	C
rx	Cohort Drug Indicator	D
sex	Gender	E
stdplac	Place of Service	C
stdprov	Provider Type	C
svcdade	Service Date	A,B,C,D
thercls	Therapeutic Class	D
tsvcdat	Date Service Ending	C

Data Sources*

- A. Administrative claims data – inpatient (facility)
- B. Administrative claims data – inpatient (professional)
- C. Administrative claims data – outpatient/ambulatory (professional and facility)
- D. Administrative claims data – pharmacy
- E. Enrollment/coverage data (2 or more years)

High-Value Health Care Project - Characterizing Episodes and Costs of Care (C3)
Data Elements Required to Calculate C3 Measures

<u>Measure Component</u>	<u>Required Variables</u>
Standardized Prices*	enrolid, ndcnum, pay, qty, drg, pproc, ..., pprocn.
Exclusions and standard coverage definition	enrolid, pdx, dx1, ..., dxn, age, svcddate, pproc, pproc1, ..., pprocn, pay, qty, revcode, memdays, rx, stdplac, proctyp.
Cohort Definition	enrolid, svcddate, pdx, pdx1, ..., pdxn, pproc1, ..., pprocn, pay, qty, sex, age, thercls, dstatus, stdplac, billtyp, fachdid, revcode.
Related Resource Use	enrolid, facprof, pay, qty, pproc1, ..., pprocn, svcddate, admdate, disdate, pdx, dx1, ..., dxn, drg, ndcnum, thercls, genmme, prodnme, daysupp, procmo, mastfrm.
Output and Attribution	enrolid, svcddate, standardized price variables*, BETOS**, pproc1, ..., pprocn, pdx, dx1, ..., dxn, egeoloc, region, provid, stdprov, age, sex, physid.

* For internal testing and validation purposes, drug prices were calculated by taking the average of 2006 and 2007 Marketscan prices, inpatient facility prices were computed by calculating average daily price by DRG from 2007, and outpatient and service prices were constructed by calculating the mean price by procedure code within the Marketscan dataset.

** Berenson-Eggers Type of Service – Categorizes Health Care Procedure Coding System (HCPCS) procedure codes in order to analyze health care expenditures. See link for full description.
http://www.cms.hhs.gov/hcpcsreleasecodesets/20_betos.asp

High-Value Health Care Project - Characterizing Episodes and Costs of Care (C3)
Data Elements Required to Calculate C3 Measures

<u>Condition (Workgroup)</u>	<u>Measure Name</u>	<u>Abbreviation</u>
Acute Myocardial Infarction (AMI)	Episode-of-Care for 30 days Following Onset	AMI1
Acute Myocardial Infarction (AMI)	Episode-of-Care for Post-Acute Period (Days 31-365 Days Post-Event)	AMI2
Asthma	Episode-of-Care for Patients with Asthma over a 1-year Period	ASTH
Breast Cancer	Episode-of-Care for 60-Day Period Preceding Breast Biopsy	BB
Breast Cancer	Episode-of-Care for Treatment in Newly Diagnosed Cases of Breast Cancer over a 15-month Period	BCT
Chronic Obstructive Pulmonary Disease (COPD)	Episode-of-Care for Patients with Stable COPD over a 1-year Period	COPD1
Chronic Obstructive Pulmonary Disease (COPD)	Episode-of-Care for Patients with Unstable COPD over a 1-year Period	COPD2
Colon Cancer	Episode-of-Care for 21-Day Period Around Colonoscopy	COL
Colon Cancer	Episode-of-Care for Treatment of Localized Colon Cancer	CCT
Congestive Heart Failure (CHF)	Episode-of-Care for Management of CHF Over 1-Year Period	CHF1
Congestive Heart Failure (CHF)	Episode-of-Care for Post Hospitalization Management of CHF over 4-Month Period	CHF2
Coronary Artery Disease (CAD)	Episode-of-Care for Management of Chronic CAD Over 1-Year Period	CAD1
Coronary Artery Disease (CAD)	Episode-of-Care for Management of CAD Post Revascularization Over 1-Year Period	CAD2
Diabetes	Episode-of-Care for Diabetes Over 1-Year Period	DIAB
Low Back Pain	Episode-of-Care for Simple Non-Specific Lower Back Pain (Acute and Sub-Acute)	LBP1
Low Back Pain	Episode-of-Care for Acute/Sub-Acute Lumbar Radiculopathy With or Without Lower Back Pain	LBP2
Pneumonia	Episode-of-Care for Community-Acquired Pneumonia Hospitalization	PN1
Pneumonia	Episode-of-Care for Ambulatory Pneumonia Episode	PN2



American Board
of Medical Specialties

Higher standards. Better care.®

Research and Education Foundation

Analytic Findings: Chronic Congestive Heart Failure Episode of Care

Overview of Analyses Presented for CHF Episode*

- Denominator Attrition
- Related and Non-related Services
- Resource Use, Attribution and
- Risk Adjustment


** The following results are based on the measure specification at different points in time, so the numbers are not always consistent, but they are not substantively different.*

Denominator Attrition

- Summarizes the initial denominator based on the workgroup's specifications
- Describes the percentage of enrollees removed from the analysis due to NCQA exclusions or other criteria.

Chronic CHF Measure Denominator

- 12 months of CHF care for patient with 2+ CHF ambulatory care visits over preceding and measurement years (at least 1 visit more than 1 month before measurement year)
- Measurement window: January 1, 2007 – December 31, 2007
- 2006-2007 test data - Marketscan
- Note: exclusions are not additive (double-counting occurs often)



Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Resource Use by Type of Service: Chronic CHF

Description	Mean	% of Total	5th %	25th %	50th %	75th %	95th %
Inpatient Facility Charge	\$597	17%	\$0	\$0	\$0	\$0	\$3,382
Durable Medical Equipment	\$178	5%	\$0	\$0	\$0	\$0	\$1,189
Imaging	\$454	13%	\$0	\$0	\$159	\$593	\$1,702
Evaluation and Management	\$341	10%	\$0	\$63	\$157	\$361	\$1,284
Other Services	\$56	2%	\$0	\$0	\$0	\$0	\$42
Procedures	\$184	5%	\$0	\$0	\$0	\$0	\$1,128
Tests	\$271	8%	\$0	\$20	\$117	\$354	\$1,053
Unclassified	\$18	1%	\$0	\$0	\$0	\$0	\$0
Drug Charges	\$1,412	40%	\$0	\$410	\$1,214	\$2,094	\$3,623
Sum of charges	\$3,511	100%	\$104	\$1,192	\$2,415	\$4,142	\$9,869

Related and Non-Related Services

- Examines most frequent related and non-related resource use by BETOS category
 - Evaluation and Management Visits, Procedures, Imaging, Tests, Durable Medical Equipment, Admissions and Medications.
- Results are presented to the workgroup to examine the face validity of episodes.

Top 20, CHF-related E&M, Chronic Episode

- 10% of total episode costs

CPT	Svcs.	Cost	% of Svcs	% of Cost	Description
99214	8,907	\$814,640	26.4%	26.2%	Office or other outpatient visit, established patient
99213	8,765	\$538,426	26.0%	17.3%	Office or other outpatient visit, established patient
99232	2,938	\$226,112	8.7%	7.3%	Subsequent hospital care for E&M care
99285	665	\$182,156	2.0%	5.8%	ED visit for E&M care
99233	1,524	\$165,013	4.5%	5.3%	Subsequent hospital care for E&M care
99215	1,203	\$159,401	3.6%	5.1%	Office or other outpatient visit, established patient
99291	478	\$150,638	1.4%	4.8%	Critical care, E&M care
99223	483	\$92,128	1.4%	3.0%	Initial hospital E&M care
99222	182	\$73,279	0.5%	2.4%	Initial hospital E&M care
99211	2,899	\$72,286	8.6%	2.3%	Office or other outpatient visit, established patient
99254	410	\$69,797	1.2%	2.2%	Inpatient consultation for a new or established patient
99244	319	\$62,940	0.9%	2.0%	Office consultation for a new or established patient
99255	239	\$56,600	0.7%	1.8%	Inpatient consultation for a new or established patient
99245	208	\$52,008	0.6%	1.7%	Office or other outpatient visit, established patient
99212	1,079	\$46,869	3.2%	1.5%	Office or other outpatient visit, established patient
99284	246	\$43,377	0.7%	1.4%	ED visit for E&M care
99231	718	\$34,864	2.1%	1.1%	Subsequent hospital care for E&M care
99238	401	\$34,746	1.2%	1.1%	Hospital discharge day management, 30 minutes or less
99239	218	\$26,353	0.6%	0.8%	Hospital discharge day management, more than 30 minutes
99292	76	\$21,897	0.2%	0.7%	Critical care, E&M care
Total	33,761	\$3,114,265	100.0%	100.0%	

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

CHF Non-related E&M, Top 20 ICD-9 Codes, Chronic Episode

ICD-9 Code	Related	Not Related	Related Costs	Non-Related Costs
25000-Dm II wo Cmp Nt St Uncntr	96	4,874	\$7,871	\$413,293
78650-Chest Pain NOS	112	1,780	\$14,685	\$270,867
41401-Crnry AthrscI Natve Vssl	185	2,918	\$15,053	\$257,704
4011 -Benign Hypertension	140	2,851	\$11,050	\$230,009
4019 -Hypertension NOS	92	2,234	\$7,873	\$191,429
25002-Dm II wo Cmp Uncntrld	31	2,149	\$2,815	\$189,602
41400-Cor Ath Unsp Vsl Ntv/Gft	90	1,434	\$6,826	\$125,075
496 -Chr Airway Obstruct NEC	81	1,278	\$8,361	\$118,948
486 -Pneumonia, Organism NOS	66	857	\$8,262	\$105,863
4660 -Acute Bronchitis	29	1,070	\$2,211	\$86,515
49121-Obs Chr Bronc W(Ac) Exac	42	710	\$6,863	\$86,476
7242 -Lumbago	5	1,010	\$614	\$82,427
7802 -Syncope & Collapse	7	582	\$1,140	\$78,661
78900-Abdmnal Pain Unspcf Site	9	705	\$1,185	\$76,461
5849 -Acute Renal Failure NOS	56	645	\$5,884	\$74,485
78659-Chest Pain NEC	19	478	\$2,478	\$71,456
V709 -General Medical Exam NOS	0	550	\$0	\$71,411
6826 -Cellulitis of Leg	15	708	\$2,409	\$68,634
5853 -Chr Kidney Dis Stage III	5	694	\$451	\$63,951
2859 -Anemia NOS	11	762	\$1,106	\$63,541
Grand Total	33,082	104,177	\$3,054,415	\$9,673,070

Top 20, CHF-related procedures, Chronic Episode

- 5% of total episode costs

CPT	Svcs.	Cost	% of Svcs	% of Cost	Description
33249	230	\$319,098	6.9%	18.9%	Insertion or repositioning of electrode lead(s) for pacemaker
93510	531	\$250,459	16.0%	14.9%	Left heart catheterization, retrograde
00534	132	\$105,835	4.0%	6.3%	Anesthesia for insertion or replacement of pacemaker
00537	92	\$105,457	2.8%	6.3%	Anesthesia for cardiac electrophysiologic procedures
93526	138	\$92,964	4.2%	5.5%	Combined right heart cath and retrograde left heart cath
93651	41	\$68,427	1.2%	4.1%	Intracardiac catheter ablation of arrhythmogenic focus
33240	88	\$61,668	2.7%	3.7%	Insertion of pacemaker
93620	57	\$61,510	1.7%	3.7%	Comprehensive electrophysiologic evaluation
33225	87	\$51,622	2.6%	3.1%	Insertion of pacing electrode for left ventricular pacing
93503	81	\$29,117	2.4%	1.7%	Insertion of flow directed catheter (eg, Swan-Ganz)
93508	61	\$28,090	1.8%	1.7%	Catheter placement in coronary artery
92960	113	\$27,256	3.4%	1.6%	Cardioversion, elective, electrical conversion of arrhythmia
92980	21	\$24,646	0.6%	1.5%	Transcatheter placement of an intracoronary stent
93501	61	\$23,090	1.8%	1.4%	Right heart catheterization
00410	65	\$22,634	2.0%	1.3%	Anesthesia for procedures on the integumentary system
33244	17	\$19,645	0.5%	1.2%	Removal of pacemaker electrodes
93613	34	\$19,323	1.0%	1.1%	Intracardiac electrophysiologic 3-dimensional mapping
93650	19	\$17,777	0.6%	1.1%	Intracardiac catheter ablation of atrioventricular node function
33241	74	\$16,711	2.2%	1.0%	Removal of pacemaker pulse generator
33208	19	\$15,908	0.6%	0.9%	Insertion or replacement of pacemaker
Total	3,312	\$1,685,025	100.0%	100.0%	

Common CHF non-related procedures, Chronic Episode

CPT	Label	Related	Not Related	Related Costs	Non-Related Costs
97110	Therapeutic procedure, one or more areas, each 15 minutes; the	34	4,823	\$1,840	\$269,813
66984	Extracapsular cataract removal with insertion of intraocular lens	0	237	\$0	\$219,061
92980	Transcatheter placement of an intracoronary stent(s), percutane	21	172	\$24,646	\$213,277
27447	Arthroplasty, knee, condyle and plateau; medial AND lateral com	0	108	\$0	\$167,701
45378	Colonoscopy, flexible, proximal to splenic flexure; diagnostic, wit	0	396	\$0	\$165,429
00790	Anesthesia for intraperitoneal procedures in upper abdomen inc	3	177	\$4,263	\$156,121
67228	Treatment of extensive or progressive retinopathy, one or more	0	112	\$0	\$148,415
00562	Anesthesia for procedures on heart, pericardial sac, and great ve	2	67	\$2,995	\$141,291
97140	Manual therapy techniques (eg, mobilization/ manipulation, mar	28	3,498	\$1,103	\$138,987
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa	19	1,490	\$1,867	\$131,849
45385	Colonoscopy, flexible, proximal to splenic flexure; with removal o	0	217	\$0	\$120,853
43239	Upper gastrointestinal endoscopy including esophagus, stomach,	0	399	\$0	\$119,124
00810	Anesthesia for lower intestinal endoscopic procedures, endoscop	1	323	\$398	\$118,978
45380	Colonoscopy, flexible, proximal to splenic flexure; with biopsy, si	0	236	\$0	\$107,766
33533	Coronary artery bypass, using arterial graft(s); single arterial gra	3	35	\$6,140	\$106,687
00142	Anesthesia for procedures on eye; lens surgery		225	\$0	\$84,385
00740	Anesthesia for upper gastrointestinal endoscopic procedures, en	2	206	\$997	\$78,890
01402	Anesthesia for open or surgical arthroscopic procedures on knee	0	97	\$0	\$77,477
00630	Anesthesia for procedures in lumbar region; not otherwise speci	0	55	\$0	\$72,850
67210	Destruction of localized lesion of retina (eg, macular edema, tum	0	91	\$0	\$72,446
Grand Total		1,706	19,579	\$1,182,725	\$3,851,454

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Top 20, CHF-related Imaging, Chronic Episode

- 13% of total episode costs

CPT	Svcs.	Cost	% of Svcs	% of Cost	Description
93307	5,188	\$1,012,855	13.7%	24.4%	Echocardiography, transthoracic
78465	1,528	\$716,770	4.0%	17.3%	Myocardial perfusion imaging; tomographic (SPECT)
93325	5,179	\$514,877	13.7%	12.4%	Doppler echocardiography color flow velocity mapping
93320	5,172	\$459,693	13.7%	11.1%	Doppler echocardiography, pulsed wave
71020	5,827	\$183,604	15.4%	4.4%	Radiologic examination, chest, two views
78478	1,487	\$134,085	3.9%	3.2%	Myocardial perfusion study with wall motion
78480	1,469	\$130,403	3.9%	3.1%	Myocardial perfusion study with ejection fraction
71010	5,210	\$124,576	13.8%	3.0%	Radiologic examination, chest; single view
A9502	463	\$108,250	1.2%	2.6%	Technetium tc-99m tetrofosmin, diagnostic
93556	696	\$68,120	1.8%	1.6%	Imaging supervision; pulmonary angiography, aortography
93555	587	\$48,374	1.6%	1.2%	Imaging supervision; ventricular and/or atrial angiography
71275	221	\$42,810	0.6%	1.0%	CT angiography, chest (noncoronary)
93545	696	\$41,537	1.8%	1.0%	Injection for coronary angiography
93312	185	\$40,348	0.5%	1.0%	Echocardiography, transesophageal
A9500	188	\$40,158	0.5%	1.0%	Technetium tc-99m sestamibi, diagnostic
78472	175	\$38,861	0.5%	0.9%	Cardiac blood pool imaging, wall motion study plus ef
93880	165	\$35,861	0.4%	0.9%	Duplex scan of extracranial arteries
A9505	188	\$34,524	0.5%	0.8%	Thallium tl-201 thallos chloride, diagnostic
71250	145	\$26,556	0.4%	0.6%	CT, thorax; without contrast material
93543	570	\$22,305	1.5%	0.5%	Injection for selective left ventricular or left atrial angiography
Total	37,761	\$4,152,528	100.0%	100.0%	

Common CHF non-related imaging, Chronic Episode

CPT	Label	Related	Not Related	Related Costs	Non-Related Costs
70553	Magnetic resonance (eg, proton) imaging, brain (including brain s	0	216	\$0	\$134,525
93880	Duplex scan of extracranial arteries; complete bilateral study	165	613	\$35,861	\$104,427
70450	Computed tomography, head or brain; without contrast materia	25	810	\$2,477	\$93,619
72148	Magnetic resonance (eg, proton) imaging, spinal canal and conte	0	205	\$0	\$93,177
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose, up to 4	188	439	\$40,158	\$89,455
74160	Computed tomography, abdomen; with contrast material(s)	17	484	\$2,792	\$85,672
72193	Computed tomography, pelvis; with contrast material(s)	26	523	\$4,213	\$84,627
73721	Magnetic resonance (eg, proton) imaging, any joint of lower extr	5	201	\$1,869	\$80,476
71260	Computed tomography, thorax; with contrast material(s)	133	388	\$20,251	\$70,823
74150	Computed tomography, abdomen; without contrast material	15	462	\$1,708	\$69,220
74170	Computed tomography, abdomen; without contrast material, fo	5	253	\$1,253	\$62,938
77057	Screening mammography, bilateral (2-view film study of each br	1	864	\$96	\$62,811
72192	Computed tomography, pelvis; without contrast material	14	397	\$1,507	\$60,670
71250	Computed tomography, thorax; without contrast material	145	274	\$26,556	\$52,918
72141	Magnetic resonance (eg, proton) imaging, spinal canal and conte	0	119	\$0	\$51,446
77080	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 d	7	460	\$710	\$49,166
78815	Positron emission tomography (PET) with concurrently acquired	3	43	\$2,686	\$47,993
93970	Duplex scan of extremity veins including responses to compressi	110	392	\$11,800	\$47,877
73221	Magnetic resonance (eg, proton) imaging, any joint of upper extr	2	103	\$671	\$44,067
72158	Magnetic resonance (eg, proton) imaging, spinal canal and conte	0	61	\$0	\$39,210
Grand Total		35,276	11,117	\$3,873,856	\$1,842,851

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Top 20, CHF-related Tests, Chronic Episode

- 8% of total episode costs

CPT	Svcs.	Cost	% of Svcs	% of Cost	Description
95811	462	\$289,040	0.7%	11.7%	Polysomnography; sleep staging, with cpap therapy
93743	2,556	\$248,452	3.7%	10.0%	Electronic analysis of pacing cardioverter-defibrillator
93000	6,542	\$230,483	9.4%	9.3%	Electrocardiogram, routine ECG with at least 12 leads
93015	1,310	\$192,334	1.9%	7.8%	Cardiovascular stress test
80061	8,014	\$154,926	11.5%	6.3%	Lipid panel
93744	1,199	\$128,093	1.7%	5.2%	Electronic analysis of pacing cardioverter-defibrillator
93641	242	\$120,377	0.3%	4.9%	Electrophysiologic evaluation of cardioverter-defibrillator
93010	6,117	\$107,226	8.8%	4.3%	Electrocardiogram, routine ECG with at least 12 leads
83880	1,885	\$86,934	2.7%	3.5%	Natriuretic peptide
93741	1,043	\$84,194	1.5%	3.4%	Electronic analysis of pacing cardioverter-defibrillator
85610	10,564	\$76,737	15.2%	3.1%	Prothrombin time
93224	188	\$43,763	0.3%	1.8%	Electrocardiographic monitoring by ECG waveform
93230	197	\$41,832	0.3%	1.7%	Electrocardiographic monitoring by ECG waveform
93642	69	\$37,315	0.1%	1.5%	Electrophysiologic evaluation of cardioverter-defibrillator
36415	6,142	\$36,555	8.8%	1.5%	Collection of venous blood by venipuncture
93236	60	\$30,328	0.1%	1.2%	Electrocardiographic monitoring by computerized monitor
80048	1,898	\$24,313	2.7%	1.0%	Basic metabolic panel
93742	252	\$22,734	0.4%	0.9%	Electronic analysis of pacing cardioverter-defibrillator
80053	1,374	\$21,477	2.0%	0.9%	Comprehensive metabolic panel
94060	299	\$17,564	0.4%	0.7%	Bronchodilation responsiveness
Total	69,472	\$2,473,806	100.0%	100.0%	

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Common CHF non-related tests, Chronic Episode

CPT	Label	Related	Not Related	Related Costs	Non-Related Costs
88305	Level IV - Surgical pathology, gross and microscopic examination	41	2,075	\$3,937	\$299,517
95810	Polysomnography; sleep staging with 4 or more additional parameters	13	337	\$6,346	\$185,745
80053	Comprehensive metabolic panel This panel must include the following: Com	1,374	6,585	\$21,477	\$105,599
85025	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelets)	1,482	7,909	\$15,916	\$89,839
95904	Nerve conduction, amplitude and latency/velocity study, each nerve	0	383	\$0	\$83,417
83036	Hemoglobin; glycosylated (A1C)	436	5,428	\$6,367	\$81,592
36415	Collection of venous blood by venipuncture	6,142	13,193	\$36,555	\$76,301
84443	Thyroid stimulating hormone (TSH)	569	2,660	\$13,660	\$69,563
80050	General health panel This panel must include the following: Com	276	1,537	\$10,842	\$60,850
95903	Nerve conduction, amplitude and latency/velocity study, each nerve	0	232	\$0	\$59,571
80048	Basic metabolic panel (Calcium, total) This panel must include the following: Com	1,898	3,924	\$24,313	\$50,976
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical	0	36	\$0	\$44,467
84153	Prostate specific antigen (PSA); total	163	1,535	\$4,511	\$43,639
85610	Prothrombin time;	10,564	5,995	\$76,737	\$42,568
95900	Nerve conduction, amplitude and latency/velocity study, each nerve	1	206	\$0	\$39,520
88307	Level V - Surgical pathology, gross and microscopic examination	2	188	\$474	\$36,910
93923	Noninvasive physiologic studies of upper or lower extremity arterial	9	241	\$1,538	\$32,337
94060	Bronchodilation responsiveness, spirometry as in 94010, pre- and	299	437	\$17,564	\$29,047
93641	Electrophysiologic evaluation of single or dual chamber pacing ca	242	57	\$120,377	\$28,207
88342	Immunohistochemistry (including tissue immunoperoxidase), each	3	142	\$1,032	\$26,818
Grand Total		55,655	59,637	\$2,154,021	\$1,756,218

CHF-related Inpatient Admissions: Chronic CHF

- 17% of total episode costs

ICD-9 Diagnosis	N	Amount	DRG	DRGlabel	N	Amount
4280 -Chf NOS	250	\$2,715,045	292	Heart failure & shock w CC	110	\$1,123,504
42731-Atrial Fibrillation	57	\$509,961	291	Heart failure & shock w MCC	62	\$986,453
4271 -Parox Ventric Tachycard	32	\$289,052	293	Heart failure & shock w/o CC/MCC	94	\$716,190
42823-Ac on Chr Syst Hrt Fail	25	\$265,311	227	Cardiac defibrillator implant w/o cardiac cath	59	\$369,280
39891-Rheumatic Heart Failure	9	\$239,179	287	Circulatory disorders except AMI, w card cath	30	\$286,174
40291-Hyp Ht Dis NOS w Ht Fail	21	\$221,291	309	Cardiac arrhythmia & conduction disorders w	26	\$252,354
40491-Hyp Hrt/Kid NOS w Hf	8	\$132,164	216	Cardiac valve & oth maj cardiothoracic proc v	5	\$251,760
42833-Ac on Chr Diast Hrt Fail	9	\$112,135	310	Cardiac arrhythmia & conduction disorders w	30	\$212,568
42732-Atrial Flutter	10	\$111,601	226	Cardiac defibrillator implant w/o cardiac cath	7	\$126,085
42821-Ac Systolic Hrt Failure	11	\$100,344	223	Cardiac defib implant w cardiac cath w AMI/H	11	\$115,814
42843-Ac/Chr Syst/Dia Hrt Fail	10	\$89,322	308	Cardiac arrhythmia & conduction disorders w	10	\$90,502
42820-Systolic Hrt Failure NOS	6	\$71,302	286	Circulatory disorders except AMI, w card cath	3	\$82,345
4589 -Hypotension NOS	6	\$70,107	251	Perc cardiovasc proc w/o coronary artery ste	13	\$79,984
42830-Diastolc Hrt Failure NOS	7	\$67,544	280	Acute myocardial infarction, discharged alive	2	\$78,398
42831-Ac Diastolic Hrt Failure	4	\$56,790	238	Major cardiovascular procedures w/o MCC	9	\$73,719
Grand Total	523	\$5,454,108	Grand Total		523	\$5,454,108

CHF Non-related Inpatient Admissions: Chronic CHF

ICD-9 Diagnosis	N	Amount	DRG	DRGlabel	N	Amount
41401-Crnry AthrscI Natve Vssl	166	\$1,473,205	3	ECMO or trach w MV 96+ hrs or PDX exc face	7	\$818,153
486 -Pneumonia, Organism NOS	111	\$1,198,211	480	Hip & femur procedures except major joint w	5	\$798,023
V5789-Rehabilitation Proc NEC	48	997679	189	Pulmonary edema & respiratory failure	57	\$794,371
51881-Acute Respiratry Failure	50	\$929,165	470	Major joint replacement or reattachment of	73	\$768,921
51884-Acute & Chronc Resp Fail	32	\$678,737	194	Simple pneumonia & pleurisy w CC	71	\$704,197
49121-Obs Chr Bronc W(Ac) Exac	63	\$648,887	392	Esophagitis, gastroent & misc digest disorder	75	\$690,766
6826 -Cellulitis of Leg	49	506908	945	Rehabilitation w CC/MCC	30	\$674,498
0389 -Septicemia NOS	30	\$488,405	191	Chronic obstructive pulmonary disease w CC	44	\$602,216
71536-Loc Osteoarth NOS-L/Leg	43	469272	603	Cellulitis w/o MCC	54	\$530,070
41071-Subendo Infarct, Initial	49	\$461,184	871	Septicemia w/o MV 96+ hours w MCC	32	\$440,445
82123-Supracondyl Fx Femur-Cl	1	435986	192	Chronic obstructive pulmonary disease w/o C	50	\$436,117
49322-Ch Obst Asth w (Ac) Exac	37	\$421,593	249	Perc cardiovasc proc w non-drug-eluting sten	71	\$429,412
42731-Atrial Fibrillation	55	\$407,252	287	Circulatory disorders except AMI, w card cath	68	\$412,001
78659-Chest Pain NEC	81	396942	313	Chest pain	93	\$400,247
5849 -Acute Renal Failure NOS	49	350919	227	Cardiac defibrillator implant w/o cardiac cath	57	\$390,931
Grand Total	2,906	\$30,770,206	Grand Total		2,906	\$30,770,206

CHF-Related Drug Costs: Chronic CHF

- Notes: Drugs compose 40% of total episode costs

Generic Drug Name	N	Amount	% of N	% of Amount
Carvedilol	21,344	\$2,348,274	10.3%	17.1%
Atorvastatin Calcium	8,384	\$1,214,910	4.1%	8.8%
Clopidogrel Hydrogen Sulfate	6,663	\$1,137,005	3.2%	8.3%
Simvastatin	5,496	\$689,570	2.7%	5.0%
Ezetimibe/Simvastatin	3,840	\$457,783	1.9%	3.3%
Warfarin Sodium	11,921	\$401,944	5.8%	2.9%
Lisinopril	13,692	\$401,821	6.6%	2.9%
Ramipril	5,016	\$376,394	2.4%	2.7%
Fenofibrate	2,612	\$361,818	1.3%	2.6%
Metoprolol Succinate	8,114	\$345,637	3.9%	2.5%
Ezetimibe	2,777	\$344,438	1.3%	2.5%
Rosuvastatin Calcium	2,774	\$335,488	1.3%	2.4%
Spirolactone	10,522	\$295,739	5.1%	2.2%
Valsartan	3,845	\$284,245	1.9%	2.1%
Furosemide	24,407	\$250,641	11.8%	1.8%
Carvedilol Phosphate	1,638	\$243,144	0.8%	1.8%
Niacin	1,561	\$241,696	0.8%	1.8%
Losartan Potassium	2,718	\$229,819	1.3%	1.7%
Amlodipine Besylate	3,884	\$225,803	1.9%	1.6%
Enoxaparin Sodium	323	\$213,508	0.2%	1.6%
Eplerenone	1,164	\$191,395	0.6%	1.4%
Pravastatin Sodium	1,356	\$183,364	0.7%	1.3%
Diltiazem Hydrochloride	2,536	\$164,560	1.2%	1.2%
Amlodipine Besylate/Benazepril HCl	1,514	\$160,438	0.7%	1.2%
Torsemide	2,202	\$134,121	1.1%	1.0%
Grand Total	206,926	\$13,754,422	100.0%	100.0%

Non-CHF-related Drug Costs: Chronic CHF

Therapeutic Class	N	Amount	% of N	% of Amount
162-Gastrointestinal Drugs Misc, NEC	12,051	\$2,401,018	5.0%	10.4%
060-Anal/Antipyr, Opiate Agonists	19,994	\$1,781,522	8.3%	7.7%
174-Antidiabetic Agents, Misc	13,654	\$1,745,631	5.7%	7.5%
234-Unclassified Agents, NEC	8,286	\$1,645,512	3.4%	7.1%
172-Antidiabetic Agents, Insulin	10,333	\$1,612,892	4.3%	7.0%
069-Psychother, Antidepressants	16,852	\$1,524,371	7.0%	6.6%
166-Adrenals & Comb, NEC	7,211	\$781,977	3.0%	3.4%
068-Anticonvulsants, Misc	3,973	\$774,613	1.6%	3.3%
055-Vasodilating Agents, NEC	173	\$558,237	0.1%	2.4%
181-Immunosuppressants, NEC	638	\$547,868	0.3%	2.4%
042-Hematopoietic Agents, NEC	273	\$482,110	0.1%	2.1%
085-Diabetes Mell/Diab Supply, NEC	4,117	\$476,065	1.7%	2.1%
021-Antineoplastic Agents, NEC	1,070	\$459,708	0.4%	2.0%
027-Sympathomimetic Agents, NEC	5,718	\$450,912	2.4%	1.9%
077-CNS Agents, Misc.	2,583	\$417,314	1.1%	1.8%
075-Anxiolytic/Sedative/Hypnotic NEC	5,509	\$414,349	2.3%	1.8%
001-Antihistamines & Comb, NEC	5,396	\$390,050	2.2%	1.7%
049-Cardiac, Antiarrhythmic Agents	3,498	\$384,930	1.4%	1.7%
070-Psychother, Tranq/Antipsychotics	1,296	\$382,175	0.5%	1.7%
059-Analg/Antipyr, Nonsteroid/Antiinflam	4,957	\$336,507	2.1%	1.5%
173-Antidiabetic Ag, Sulfonylureas	7,474	\$321,009	3.1%	1.4%
024-Anticholinergic, NEC	2,167	\$320,750	0.9%	1.4%
107-Repl Preps, Potassium Supp	15,021	\$318,069	6.2%	1.4%
016-Quinolones, NEC	3,538	\$256,521	1.5%	1.1%
Grand Total	241,405	\$23,159,369	100.0%	100.0%

CHF Provider Attribution

- Identify the provider or providers “responsible” for the patient’s care during the course of an episode
- Support a comparison across providers rather than simply across all episodes, which may be reflective of a normal distribution of costs population-wide

Proposed Attribution Model

- “Tiered” attribution model, depending on the number of each episode’s CHF-related E&M visits during the measurement period and the distribution of those visits across providers
 - Requires that the episode has at least 1 E&M visit and that at least 70% of the E&M visits include valid provider ID numbers
- Tier 1 – Single Attribution: if one provider ID has at least 70% of an episode’s E&M visits, that provider will be attributed the episode
- Tier 2 – “Multiple” Attribution: if no provider has at least 70% of the episode’s E&M visits, any provider with at least 30% will be attributed the episode
- Tier 3 – No Attribution: if no provider has at least 30% of the episode’s E&M visits, no provider will be attributed the episode

Chronic CHF Episode: Attribution Testing

- Required: 1) ≥ 1 E&M visit for CHF care; 2) $\geq 70\%$ of E&M visits with valid provider IDs
- 1 provider with $\geq 70\%$ of E&M visits – single attribution only; else
- 1+ providers with $\geq 30\%$ of E&M visits – up to 3 providers attributed episode; else
- No attribution

Chronic CHF Measure Denominator	7,297	100.0%
No related E&M visits during measurement year	5	0.1%
Episode's E&M visits have insufficient provider IDs	3,914	53.6%
Episodes to be attributed	3,378	46.3%
Single attribution	2,615	77.4%
Multiple attribution	735	21.8%
<i>2 providers</i>	692	20.5%
<i>3 providers</i>	43	1.3%
No attribution	28	0.8%

Note: Among episodes attributed to a single provider, 91% had one provider with at least 70% of the episode's CHF-related E&M visits. In the remaining episodes, the attributed provider had between 30% and 70% of related E&M visits.

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Identifying Variability in CHF-specific Resource Use

- Analyses intended to identify trends in the observed variability in resource use for episodes of CHF management
- Variability measured at the following levels:
 - Region
 - State
 - Specialty
 - Individual Provider

Chronic CHF: Mean Resource Use by Type of Service, All Episodes*

Description	Mean	% of Total	5th %	25th %	50th %	75th %	95th %
Inpatient Facility Costs	\$2,841	40%	\$0	\$0	\$0	\$0	\$17,172
Durable Medical Equipment	\$209	3%	\$0	\$0	\$0	\$0	\$1,395
OP Facility Costs	\$709	10%	\$0	\$0	\$0	\$0	\$3,168
Imaging	\$578	8%	\$0	\$20	\$508	\$805	\$1,892
Evaluation and Management	\$571	8%	\$65	\$130	\$258	\$540	\$2,141
Other Services	\$75	1%	\$0	\$0	\$0	\$0	\$325
Procedures	\$305	4%	\$0	\$0	\$0	\$0	\$1,758
Tests	\$360	5%	\$0	\$56	\$190	\$462	\$1,255
Unclassified	\$37	1%	\$0	\$0	\$0	\$0	\$0
Drug Costs	\$1,493	21%	\$0	\$608	\$1,279	\$2,124	\$3,670
Sum of Costs	\$7,178	100%	\$544	\$1,752	\$3,077	\$5,562	\$29,484

* Analysis limited to those episodes that could be attributed to one or more providers and had non-zero CHF-related costs (n=3,378)

Chronic CHF: Resource Use by Type of Service vs. Overall Mean, by Region

Description	Mean	Northeast	North Central	South	West
N	3,378	145	403	2,318	504
Inpatient Facility	\$2,841	1.10	1.00	1.04	0.81
DME	\$209	0.43	1.06	1.00	1.12
OP Facility	\$709	0.77	1.56	0.90	1.08
Imaging	\$578	0.87	0.91	1.05	0.88
E&M	\$571	0.94	1.04	1.02	0.90
Other Services	\$75	1.19	0.45	1.04	1.23
Procedures	\$305	1.18	0.78	1.04	0.97
Tests	\$360	1.10	1.02	1.03	0.85
Unclassified	\$37	0.00	0.06	1.30	0.69
Drug Costs	\$1,493	0.94	0.99	1.01	0.98
Total	\$7,178	0.98	1.03	1.02	0.91

* Analysis limited to those episodes that could be attributed to one or more providers and had non-zero CHF-related costs (n=3,378)

Chronic CHF: Resource Use by Type of Service vs. Overall Mean, by State

Description	Mean	TX	GA	CA	TN	SC	MS	AL	FL	IL	OH
N	3,378	550	510	283	263	246	158	147	94	88	82
Inpatient Facility	\$2,841	0.87	1.17	0.93	1.47	0.63	0.77	1.64	0.66	1.66	1.77
DME	\$209	1.01	1.26	1.02	1.19	0.67	0.39	0.94	0.78	1.10	1.27
OP Facility	\$709	2.22	0.03	0.07	0.45	0.93	0.05	1.08	0.25	2.41	1.80
Imaging	\$578	1.04	0.96	0.83	1.31	1.12	0.75	0.94	1.33	0.97	0.97
E&M	\$571	0.92	1.22	0.89	1.20	0.71	0.71	1.17	1.12	1.29	1.49
Other Services	\$75	0.71	2.43	1.90	1.01	0.29	0.34	0.67	0.66	0.29	0.61
Procedures	\$305	1.08	0.90	0.67	1.61	0.94	0.24	1.14	0.72	1.28	0.91
Tests	\$360	1.19	0.99	0.80	1.08	1.01	0.56	0.84	1.11	1.44	0.84
Unclassified	\$37	0.11	3.52	1.18	3.67	0.51	0.06	0.26	0.00	0.03	0.02
Drug Costs	\$1,493	0.99	0.89	0.93	1.14	0.97	0.90	1.16	1.01	0.98	1.03
Total	\$7,178	1.07	0.99	0.83	1.25	0.80	0.67	1.29	0.81	1.44	1.41

* Analysis limited to those episodes that could be attributed to one or more providers and had non-zero CHF-related costs (n=3,378)

Chronic CHF: Resource Use by Type of Service vs. Overall Mean, by Specialty*

- Results presented for high-volume specialties: Top 5

Description	Mean	Cardiology	Internal Medicine	Family Practice	Medical Doctor NEC	Multi-Specialty Group
N	3,378	1,480	775	644	299	262
Inpatient Facility	\$2,841	1.07	0.96	0.91	0.79	1.00
DME	\$209	0.80	1.15	1.07	0.67	1.15
OP Facility	\$709	1.09	0.73	0.71	0.68	0.99
Imaging	\$578	1.19	0.96	0.86	0.91	0.85
E&M	\$571	0.97	1.05	1.00	0.82	0.81
Other Services	\$75	1.15	0.54	0.81	0.29	1.62
Procedures	\$305	1.40	0.93	0.82	0.55	0.77
Tests	\$360	1.15	1.03	0.89	0.85	0.92
Unclassified	\$37	0.84	1.12	1.44	0.07	1.28
Drug Costs	\$1,493	1.06	0.98	0.93	1.00	0.93
Total	\$7,178	1.08	0.95	0.90	0.81	0.95

* Individual episodes may be attributed to as many as three providers, and so the resource use associated with any given episode may be reflected in the results for up to three provider specialties; cardiologists will be the subject of further analysis on slide 8

Risk Adjustment

- Testing of risk adjustment models
- Apply risk adjusted results to produce a provider specific summary report.

Risk Adjustment Model Specification

- Test 12 different model specifications
 - Logged GLM model using gamma distribution
 - Full list of recommended comorbidities
 - Only recommended comorbidities that are statistically significant
 - Only recommended comorbidities that are statistically significant + additional comorbidities flagged for “empirical analysis” (all, significant only)
 - All HCCs & all statistically significant HCCs
 - Normal GLM model (estimates in dollars)
 - Same tweaks as above

Chronic CHF Episode Risk Adjustment Matrix

Model #	Independent Variables						Distribution	Link function
	WG Specified	WG specified p<0.1	Test conditions	Test conditions p<0.1	All HCCs	All HCCs p<0.1		
1	X						Gamma	Log
2		X					Gamma	Log
3		X	X				Gamma	Log
4		X		X			Gamma	Log
5	X						Normal	Identity
6		X					Normal	Identity
7		X	X				Normal	Identity
8		X		X			Normal	Identity
9					X		Gamma	Log
10						X	Gamma	Log
11					X		Normal	Identity
12						X	Normal	Identity

Document for internal discussion purposes. Do not distribute or cite.

Data Source: Thomson Reuters Healthcare Copyright © 2009 The TRH Group, Inc. All Rights Reserved.

Sample Provider Summary Report

Report for Physician #xxxxx

Provider type = insert specialty

	MD	Peer Group	Non-Peer Group	National Avg
Episodes	21	9,512	68,434	77,967
Observed Costs*				
Average	\$ 897	\$ 992	\$ 1,481	\$ 1,421
Min	\$ 45	\$ 12	\$ 12	\$ 12
Median	\$ 747	\$ 538	\$ 853	\$ 807
Max	\$ 2,797	\$ 11,140	\$ 11,140	\$ 11,140
Predicted Costs				
Average	\$ 1,400	\$ 1,083	\$ 1,523	\$ 1,470
Min	\$ 966	\$ 831	\$ 831	\$ 831
Median	\$ 1,126	\$ 1,039	\$ 1,502	\$ 1,392
Max	\$ 2,345	\$ 8,286	\$ 6,883	\$ 8,286
Observed-to-Expected Ratio				
Average	0.64	0.91	0.98	0.97
Min	0.03	0.01	0.01	0.01
Median	0.54	0.51	0.58	0.57
Max	1.54	13.40	13.40	13.40
% ≥ 2.0	0%	10.9%	11.6%	11.5%
% ≥ 2.5	0%	7.0%	7.7%	7.6%

% ≥ 75th percentile peers 50.0% (0%, 20.9%)

* Observed costs adjusted for outliers (winsorized)

Notes:

- Use Model 12
- Includes all episodes